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Abstract 
Chad Roberts Deisenroth 
Regulation and function of mitochondrial Hep27: a novel modulator of the Mdm2-p53 
pathway 
(Under the direction of Yanping Zhang, Ph.D.) 
 
The ever-expanding role of p53 in cellular metabolism, apoptosis, and cell 
cycle control has led to increasing interest in defining the stress response pathways 
that regulate Mdm2. In an effort to identify novel Mdm2 binding partners, we 
performed a large-scale immunoprecipitation of Mdm2 in the osteosarcoma U2OS 
cell line. One significant binding protein identified was Hep27, a member of the 
short-chain alcohol dehydrogenase/reductase (SDR) family of enzymes. Here we 
demonstrate the Hep27 pre-protein contains an N-terminal mitochondrial targeting 
signal that is cleaved following mitochondrial import, resulting in mitochondrial matrix 
accumulation of mature Hep27. A fraction of mitochondrial Hep27 translocates to the 
nucleus, where it binds to Mdm2 in the central domain, resulting in attenuation of 
Mdm2 mediated p53 degradation. In addition, Hep27 is regulated at the 
transcriptional level by the proto-oncogene c-Myb and is required for c-Myb induced 
p53 activation. Breast cancer gene expression analysis correlated estrogen receptor 
(ER) status with Hep27 expression and p53 function, providing a potential in vivo link 
between estrogen receptor signaling and p53 activity. Our data demonstrate a 
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unique ER-c-Myb-Hep27-Mdm2-p53 mitochondria-to-nucleus signaling pathway that 
may have functional significance for ER positive breast cancers.  
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Chapter 1 
 
Introduction 
 
 
The discovery of p53 
Over three decades of intense research have helped to shape and define the 
story behind arguably one of biology’s most famous genes, p53. Since the discovery 
of p53 in 1979 (93, 101), a wealth of data has been generated to highlight the 
importance of p53 in a wide range of biological functions. As a central stress 
response regulator, p53 acts as a master regulatory switch to monitor cellular 
homeostasis. As such, this former “Molecule of the Year” (87) has been dubbed the 
“guardian of the genome” (92), the “death star” (210), and the “cellular gatekeeper” 
(96). Since over 50% of cancers demonstrate underlying defects in the p53 pathway, 
this “gatekeeper” remains at the pinnacle of cellular surveillance to regulate the 
balance of cell growth and proliferation (209). 
2 
 
The initial discovery of p53 started with the co-precipitation of an 
approximately 54-56 kDa protein from murine cell lines that had been transformed 
with the viral SV-40 large T-antigen (18, 88, 93, 101). Since an in vivo association 
was found to occur between the large T-antigen and the 54kDa protein (93), it was 
found in nearly all SV-40 transformed cells, as well as some embryonic carcinoma 
cells (101), and a partial peptide sequence was shown to be unlike anything 
identified from known SV-40 viral genes (88), the 54kDa protein was postulated to 
be encoded by the cellular genome.  
In addition to studies in transformed cell lines, antisera collected from BALB/c 
mice with methylcholanthrene-induced sarcomas revealed a 53 kDa protein not 
found in normal adult murine fibroblasts. The same protein was also found in 
chemically-induced leukemias, spontaneously transformed fibroblasts, and cells 
transformed by simian virus 40 and murine sarcoma virus (31). Later, BALB/c mice 
injected with Abelson murine leukemia virus -transformed cells were found to 
generate antibodies that could precipitate a 50kDa protein thought to be of cellular 
origin (167).  
Initial studies of p53 levels during the cell cycle pointed towards increased 
steady state levels just prior to the initiation of DNA synthesis at the end of G1 
phase, suggesting a positive role for p53 in cell proliferation (163). Direct 
microinjection of p53 monoclonal antibodies into Swiss 3T3 mouse cells inhibited 
serum-stimulated entry into S phase, further supporting the idea that p53 could 
promote cell growth and division (118, 119). Furthermore, anti-sense mediated 
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knockdown of p53 generated clones with reduced rates of DNA synthesis and 
eventual cessation of cell proliferation (186). To lend additional support to the notion 
of p53 as an oncogene, subsequent experiments cloned the cDNA sequence from 
cancer lines to generate an expression construct capable of transforming primary 
cells (77). Using a similar approach, it was also demonstrated that p53 could 
cooperate with activated Ha-ras, a known oncogene, to transform normal embryonic 
fibroblasts (44, 153) At the time, this evidence collectively pointed towards a role for 
p53 as an oncogene capable of promoting malignant transformation.  
Observations of p53 in Friend virus-induced leukemia models revealed that 
the p53 cDNA sequence in their model was truncated, resulting in expression of a 46 
kDa protein (131). Heterogeneity of p53 expression in these models led investigators 
to look at chromosomal rearrangements in the deletion clones, thus identifying that 
the p53 locus was often deleted in cases where cells had a selective growth 
advantage (128). Additional evidence was emerging to call into question the ability of 
wild-type p53 to transform cells. Expression of wild-type p53, in conjunction with 
activated ras and myc or adenovirus E1A oncogenes, in rat embryonic fibroblasts 
caused a marked reduction in transformed foci (43, 51). Follow up phylogenetic 
analysis of murine p53 cDNA clones revealed several point mutations occurring in 
well conserved regions of the gene (195, 196). Point mutations of residues between 
amino acids 132-215 were found to activate the transforming phenotype of p53 
(128), suggesting that previous p53-mediated transformation experiments may have 
been using mutant p53.  
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The emerging evidence was beginning to shift the paradigm of p53 as an 
oncogene to one of a tumor suppressor. Analysis of patient-derived colorectal 
carcinoma specimens first reported a 75% loss of heterozygosity at the short arm of 
chromosome 17, the region where the p53 locus is located (208). Similar 
observations were made in lung cancer samples, where p53 expression was 
generally found to be low (200). At the time, Li-Fraumeni syndrome patients were 
observed to develop a wide array of cancers at a very early age. This led 
investigators to identify inherited germ-line point mutations in p53, with a strict 
correlation between inheritance of the mutant allele and the onset of neoplasms 
(108, 197).  
Mice overexpressing a mutant p53 transgene were susceptible to developing 
lung adenocarcinomas, osteosarcomas, and lymphomas, thus showing in vivo how 
mutant p53 alleles can induce tumor formation (94). One explanation for this could 
be ascribed to the dominant negative characteristic of mutant p53 which can form a 
heterodimer with wild type p53 and therefore inhibit appropriate DNA binding (121). 
Binding to DNA was found to be critical for the growth arrest and tumor suppression 
function of p53 (72). Since p53 mutation was one of the most frequently observed 
genetic anomalies in human cancer, deletion of p53 in a mouse model was 
performed to assess the true tumor suppressor capacity. Mice with homozygous 
deletions of p53 exhibited a high penetrance of spontaneous tumors by six months 
of age (36). The spectrum of tumors varied with genetic background, but the majority 
of tumors were thymic derived T-cell lymphomas (37, 76). Soon thereafter, exposure 
of p53 null mice to ionizing radiation resulted in 70% incidence of anomalies, but 
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only 7% death among developing fetuses. This in contrast to p53 wild-type mice 
bearing only 20% incidence of anomalies, but a significant 60% of apoptotic-
dependent deaths among developing fetuses (140). Further reports demonstrating 
dependence of p53 loss on developing mice to teratogen-induced damage argued in 
favor of p53 conservation as a cellular proofreader capable of protecting cells during 
development from teratogenic damage, but also in adult life from carcinogenic insult 
(14). 
Taken together, 1) p53 loss of heterozygosity and point mutation were among 
the most frequent genetic aberrations in cancer, 2) activating mutations of p53 can 
promote tumorigenesis both in cell and animal models, and 3) mice with p53 
homozygous deletion were susceptible to spontaneous tumors, all argued in favor of 
wild-type p53 acting as a tumor suppressor. The gene was conserved to monitor, or 
“proofread”, genetic anomalies during development and growth, so as to inhibit 
deleterious accumulation of genetic lesions that could otherwise affect proper 
functioning of the organism.  
 
p53 as a stress response pathway 
 
p53 has subsequently been shown to respond to a wide variety of intrinsic 
and extrinsic stressors such as DNA damage, oncogene activation, hypoxia, 
perturbation to ribosome biogenesis, and many others (Fig. 1.1). Each stress point 
6 
 
constitutes a potentially separate pathway, with different mediators to transmit the 
signal. However, they all converge on p53 to induce a downstream response 
through activation of different genetic programs, the hallmark responses being cell 
cycle arrest, apoptosis, or senescence (97).  
The half-life of p53 is short, owing to rapid turnover by the negative regulator 
Mdm2. This makes post-translational modification and stabilization the primary 
components for inducing transactivation functions of p53. The primary mechanism of 
most stress signals that channel through p53 is to modify and subsequently inhibit 
the interaction of Mdm2 with p53, thereby promoting p53 stability, transactivation, 
and induction of downstream genetic programs resulting in different biological 
outcomes (115). For instance, DNA damage activates the ataxia-telangiectasia 
mutated (ATM) and ataxia-telangiectasia and Rad-3 related (ATR) protein kinases, 
in turn promoting CHK1 or CHK2 phosphorylation to transduce the signal to p53 
which finally gets phosphorylated (185). p53 activation promotes induction of genes 
involved in cell cycle arrest and DNA repair. These responses to genotoxic stress 
are governed by p53 as evidenced by defective double-strand break repair, 
defective cell cycle control, and enhanced sensitivity to ionizing radiation in cells 
from ataxia-telangiectasia patients. 
A major question in the p53 field pertains to the underlying mechanism driving 
the decision to promote cell cycle arrest or induce apoptosis. The answer is likely 
complex and probably involves everything from post-translational modifications of 
p53 and Mdm2, chromatin alterations of p53 target genes, contribution of co-factors, 
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cell type, and cellular environment. However, one common denominator is the 
overall accumulated level of the p53 protein itself. The differential transactivation 
capabilities of p53 have been found to depend on both the intrinsic DNA binding 
affinity of p53 to various p53 response elements, as well as the overall protein 
levels. The same study also demonstrated genes involved in cell cycle arrest have 
high affinity p53 response elements and those involved in apoptosis have lower 
affinities for p53 (75). In response to mild cellular stress, p53 may exhibit a strictly 
nuclear function by inducing high affinity downstream target genes involved in cell 
cycle arrest. Intermediate levels of stress or accumulating levels of p53 may retain 
strictly nuclear function, but begin to access lower affinity pro-apoptotic genes 
pushing the cell just below the threshold of apoptosis induction. Under conditions of 
extreme stress or greatly accumulated levels of p53, both high and low p53 target 
genes are maximally transcribed. In addition, maximal levels of p53 accumulation 
may promote p53 export to the cytosol where transcription-independent roles in 
apoptosis can be executed. 
There are a number of amino acid residues in p53 that are post-translationally 
modified and have been postulated to promote p53 stability (217). These 
modifications may act as a barcode for directing the response of p53 to any number 
of upstream signals (132). Serine 15 (5, 17, 134) and Serine 20 (184, 206) of p53 
have been reported to be prime targets of ATM/ATR kinases following DNA damage. 
Phosphorylation at these sites was purported to disrupt the ability of Mdm2 to bind 
p53 and promote p53 export, thereby preventing transactivation of target genes. Site 
specific mutation of Ser15 to alanine (Serine 18 in mice) suggested that this site was 
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necessary for a maximal response to DNA damage (19). However, others argued 
that the essential function of p53 phosphorylation is to facilitate acaetylation of the 
protein (20). Studies have gone on to show that phosphorylation at Ser15 may not 
be essential for C-terminal acetylation of p53 (19). Similar studies have suggested 
the same for Ser20 (Ser23 in mice), together calling into question the necessity of 
p53 post-translational modification (216).  
Following upstream activation and protein stabilization, p53 directs 
downstream events; most notably regulation of the cell cycle. One of the most well 
characterized target genes of p53 is p21 (WAF1, Cip-1) (41). Multiple p53 binding 
sites are located in regions just up and downstream of the transcription start site, 
making p21 a high affinity target for p53. After induction, p21 binds to an array of 
cyclin-CDK complexes such as cyclin E/A–Cdk2 to block respective kinase activity 
on the retinoblastoma inhibitor of E2F. The result is inhibition through the G1 to S 
transition of the cell cycle, effectively stalling DNA replication initiation. Mice deficient 
for p21, however, still develop normally and demonstrate only a partial deficiency in 
G1 checkpoint control, suggesting redundancy in G1-S checkpoint surveillance (32).  
While cell cycle arrest is a reversible process, the induction of senescence, or 
nearly permanent exit from the cell cycle, is also a process mediated by p53. Normal 
human and murine cells are known to undergo a finite number of cell divisions, only 
to undergo a series of morphological and metabolic changes, as well as gene 
expression alterations, that define the senescent state. In human cells, p53 levels 
and p21 levels increase with multiple passages of the cells, presumably through 
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intrinsic cellular signals related to progressive shortening of telomeres and 
increasing genomic instability (164).  In addition, other signals like activated RAS 
can induce premature cell senescence (219), where in vivo p53 mediates changes in 
the tissue microenvironment through induction of inflammatory cytokines that recruit 
macrophages to eliminate the senescent cell from the population (1, 89). 
The response mediated by p53 to induce apoptosis can occur at multiple 
levels. Both the extrinsic and intrinsic apoptosis pathways converge at the level of 
caspase activation to initiate the stereotypic events of apoptosis. The intrinsic 
pathway is regulated by the pro- and anti-apoptotic activities of the Bcl-2 family of 
proteins. The Bcl-2 family can be broadly distributed into three categories: 1) pro-
survival proteins such as Bcl-XL, 2) pro-apoptotic proteins like Bax and Bak, 3) pro-
apoptogenic BH3-only proteins including Noxa and Puma (13). p53 is reported to 
directly induce transcription of a number of Bcl-2 genes, specifically Bax, Noxa, and 
Puma. Bax was the first pro-apoptotic gene shown to be directly regulated by p53 
and is able to heterodimerize with Bcl-2 to accelerate apoptosis (122). Noxa 
encodes a BH3-only member of the Bcl-2 family and acts by antagonizing pro-
survival Bcl-2 members at the level of the mitochondria to indirectly support 
mitochondrial outer membrane permeabilization (MOMP) (141). Puma, or p53 
upregulated modulator of apoptosis, is also a BH3 domain containing protein that 
can bind to Bcl-2 and promote MOMP-mediated cytochrome c release (136). In 
addition, p53 induces transcription of APAF-1, a critical component of the 
apoptosome, as well as caspase-6, an executioner caspase acting downstream of 
the activated apoptosome (82, 107). This evidence clearly demonstrates the critical 
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transcription-dependent role of p53 in regulating pro-apoptotic gene function, 
resulting in initiation of early apoptotic events. 
 Apart from the transcription-dependent functions of p53, there are other 
transcription-independent functions of p53 that contribute to the apoptotic cascade. 
For instance, p53 has been proposed to shuttle preformed FAS death receptors to 
the cell membrane (7), translocate directly to the mitochondria to promote ROS 
formation (109), and promote FADD-independent cytosolic activation of caspase 8 
(34). Overexpression of select mutant and truncated forms of p53, which are 
transcriptionally inert, have also been demonstrated to promote apoptosis (65). 
  
The discovery of Mdm2 
 
Murine Double Minute 2 (Mdm2) was the second of three Mdm genes 
originally identified from purified acentric chromosomes in a spontaneously 
transformed mouse BALB/c cell line 3T3-DM (16). These acentric chromosomes, or 
double minutes, often contain amplified genes conferring a selective growth 
advantage to cells. Mdm2 was the second of two tandem genes identified and soon 
identified to have tumorigenic potential when ectopically overexpressed (49). Later, 
Mdm2 was demonstrated to bind to p53 and block a p53 specific response (127). 
Once the human Mdm2 gene was mapped to chromosome 12q13-14, it was soon 
shown to be amplified in a subset of soft tissue tumors and osteosarcomas (144). 
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Downstream transcriptional targets of p53 identified Mdm2 as a major target, thus 
providing rationale for an autoregulatory feedback loop (Fig. 1.2). This established 
the framework for an Mdm2-p53 tumor suppressor pathway that was dysfunctional in 
a significant fraction of human cancers. 
A number of proteins in the cell are subject to degradation via the ubiquitin-
proteasome system. Three sequential enzymatic steps comprised of ubiquitin 
activation (E1), conjugation (E2), and ligation (E3) are required to ubiquitin-modify a 
target substrate (Fig. 1.3) (69). E3 ubiquitin ligases provide the substrate specificity 
for ubiquitin transfer through an isopeptide linkage on one or more lysine residues 
on the target substrate. Substrates undergo mono- or poly ubiquitination which 
serves to alter the function of a protein or target it to the 26S proteasome for 
degradation, respectively (160).  
Human Mdm2 is a 491 amino acid protein comprised of an N-terminal p53 
binding domain, a central acidic domain, a zinc finger domain, and a C-terminal 
RING domain. The RING family of E3 ligases do not form thioester bonds with 
ubiquitin, but do activate the discharge of ubiquitin from an E2 conjugating enzyme 
to the target substrate (33). Typically, under basal conditions, p53 protein levels are 
kept at a low steady-state level. In response to stress, a number of factors converge 
on Mdm2 to disrupt Mdm2-mediated turnover of p53, resulting in p53 stabilization 
and transactivation. Following the initial stress response, p53 levels dampen in an 
oscillatory pattern; with repeated pulses of p53 stabilization depending on the cell 
type and nature of the stress (91). 
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Work in mouse models has solidified the connection between Mdm2 and 
regulation of p53.  Mice generated by homologous recombination to carry a null 
allele for Mdm2 died during development, just prior to embryo implantation. 
Interestingly, the embryonic lethal phenotype could be rescued by concomitant 
deletion of p53, suggesting a role for Mdm2-directed p53 turnover during murine 
development (79, 106). Furthermore, reduction of p53 using a conditional 
hypomorphic allele of Mdm2 in mice increased radiosensitivity in a fraction of tissues 
where increased apoptosis was observed (117). Collectively this work helped to 
establish the Mdm2-p53 regulatory loop as a bona fide pathway in vivo. 
 
Regulating Mdm2 to modulate p53 function 
 
There are a multitude of cytotoxic and genotoxic stressors that converge on 
Mdm2 to elicit p53 stabilization and activation. There at least three types of stress 
that can transduce signals through Mdm2 (Fig. 1.4). The first is so-called nucleolar 
stress (also known as ribosomal stress), the second is oncogenic stress brought 
about by mitogenic overstimulation, and the third acts through the DNA damage 
response.  
The INK4a/ARF locus encodes the Alternative Reading Frame (ARF) tumor 
suppressor that has been demonstrated to be an important mediator of p53 
stabilization (183). ARF levels are normally maintained at low levels in the cell, but in 
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response to oncogenic stress such as RAS activation, c-myc overexpression, or RB 
deficiency, ARF binds to Mdm2 and inhibits Mdm2 mediated p53 ubiquitination and 
degradation (180). ARF null mice are highly prone to spontaneous tumor 
development (81), and mutation or epigenetic silencing of the CDKN2A locus 
encoding ARF is a common occurrence in mouse-derived tumors (40, 178). 
However, features of mouse ARF such as induction by oncogenic RAS or replicative 
senescence (152, 228), as well as the divergence of INK4a/ARF gene structure 
between mouse and human, brings into the question the degree of ARF-mediated 
tumor suppression in humans.  
Mdm2 is also reported to be extensively modified through a number of post-
translational modifications including ubiquitination, sumoylation, and phosphorylation 
(116). The amino terminus of Mdm2 contains two clusters of phosphorylation sites 
(67) that are partially identified to be modified by AKT (Ser166, Ser186), cyclinA-
CDK1/2 (Thr219), c-Abl (Tyr294), and CK2 (Ser269). While DNA damage is known 
to activate ATM kinase-induced phosphorylation of p53, it also targets Mdm2 at 
Ser395 for phosphorylation in vitro (113). Like phosphorylation of p53, Mdm2 
phosphorylation inhibits Mdm2 directed turnover of p53. An Mdm2 Y394F mutant 
that prevented c-Abl-dependent phosphorylation of Mdm2 at Tyr394 was shown to 
increase Mdm2 activity and subsequently downregulate p53 transactivation (58), 
supporting the notion that Mdm2 phosphorylation on multiple amino acid residues 
can block Mdm2 from binding and stimulating degradation of p53. 
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The latest players in Mdm2 regulation are a subset of ribosomal proteins. The 
earliest evidence of ribosomal protein (RP) interactions with Mdm2 occurred with the 
report of RPL5 binding to Mdm2 in a 5S rRNA-RPL5-Mdm2-p53 ribonucleoprotein 
complex, but at the time, the meaning of such an interaction was unclear (110). 
Nearly a decade later, in screens seeking out novel Mdm2 modulating proteins, the 
large subunit ribosomal proteins RPL5, RPL11, and RPL23 were all reported to bind 
to Mdm2, block the E3 ubiquitin ligase function of Mdm2, and promote p53 
accumulation (10, 28, 29, 78, 103, 224). Following these initial reports, additional 
evidence subsequently was produced to support the roles of RPS7 (21, 226), RPL26 
(142), and RPS3 (218) as Mdm2 binding partners. 
In general, the current paradigm for ribosome biogenesis, largely derived from 
studies in bacteria and yeast systems, is the coordinated assembly of equimolar 
concentrations of ribosomal proteins and ribosomal RNA to generate mature 80S 
polysomes that ensure adequate protein synthesis to maintain cellular homeostasis. 
In humans, this process requires the activity of RNA polymerase I to generate the 
47S precursor rRNA from clusters of rDNA tandem repeat genes. The precursor is 
further processed to 18S, 5.8S, and 28S rRNAs. The fourth rRNA, 5S, is transcribed 
separately by RNA polymerase III and actively imported to the nucleus for 
incorporation into the large subunit.  Members of the pool of 79 ribosomal proteins 
are actively transcribed by RNA polymerase II, exported to the cytosol for 
translation, and imported to the nucleolus for assembly.  In addition, there are over 
200 auxiliary factors that assist in the processing of rRNA, assembly of the small and 
large subunits, and finally export and maturation of the functional ribosome (12).  
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A number of reports investigating RP-Mdm2 binding have alluded to 
“nucleolar stress” as the event responsible for inducing the RP-Mdm2-p53 stress 
response. In this context, “nucleolar stress” specifically refers to perturbations of 
ribosome biogenesis and the subsequent breakdown of nucleolar structure, resulting 
in activation of p53. In part, these observations have led to the hypothesis of the 
nucleolus as a central stress response regulator for p53 activation (169).   
Altogether, it becomes clear that Mdm2 is subject to a complex array of 
regulatory mechanisms. To date, all of the aforementioned stress response 
mechanisms appear to involve regulation in the nuclear compartment of the cell, the 
area where Mdm2 activity is centered. Due to the fact that Mdm2 can be regulated in 
a variety of ways, it stands to reason that other subcellular compartments may signal 
through Mdm2 to monitor the integrity of other cellular metabolic processes.  
 
The Mdm2-p53 pathway is altered in human cancer 
 
Inactivation of the p53 tumor suppression pathway is a frequent occurrence in 
human cancer and is estimated to take place in approximately 31% of cases (61). 
The distribution of direct p53 mutation across tumor types is variable with the highest 
frequency in cancer of the colon and lung (60-65%) and the lowest in leukemias 
(10%) (194). While inactivation of p53 alone is generally insufficient to promote 
tumorigenesis, the combined “hit” of p53 loss in conjunction with activation of a 
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number of oncogenes, as well as loss of other tumor suppressors, will promote 
cellular transformation (63). Absence of p53 is thought, in part, to lead to 
accumulation of genetic lesions.  When left unchecked through inefficient DNA 
repair, selection and maintenance of positive mutations can promote genetic 
instability and ultimately malignant potential (194). 
Approximately 90% of point mutations occur in the core DNA binding domain 
of p53, with about 20% in so called “hotspot” codons (175, 245, 248, 249, and 273) 
(64). Missense mutations, or insertions/deletions, lead to expression of mutant 
protein 90% of the time, or nonsense mutations leading to the absence of protein the 
remainder of time. p53 missense mutations can be categorized into three separate 
groups: Class I affect the DNA binding surface, Class II disrupt the flexibility of the 
protein to disrupt the connections between the scaffold and DNA binding surface, 
and Class III affect the tertiary structure of the whole protein (64). There is a strict 
correlation between DNA binding activity and suppression of cell growth, indicating 
that point mutations impacting the capacity of p53 to transactivate downstream 
target genes is an essential component to tumor suppression (147, 166). However, 
the ability of p53 mutants to negatively impact wild-type p53 function can widely vary 
by cell type and codon mutation (52), but overall the conservation of p53 mutation 
need generally to provide a selective growth advantage to a cell.  
In cancers where wild-type p53 is conserved, modifications to upstream 
components of the axis are often observed. Amplification of Mdm2 protein levels by 
gene amplification, gene overexpression, or hyperactive mRNA translation is 
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estimated at 7% overall for all spectra of cancer types. Soft tissue sarcomas (20%) 
and osteosarcomas (16%) have the highest rates of Mdm2 overexpression. In 
addition, the prevalence of Mdm2 amplification and p53 mutation were found to be, 
for the most part, mutually exclusive events, implying that inactivation of the p53 
pathway requires aberrations only at single points along the axis (126).  
The two gene products, p16Ink4a and p14Arf  of the Ink4a-Arf locus often 
undergo genetic modification to disable one or both components. p16INK4a  blocks 
progression through the cell cycle by inhibiting complex formation of CDK4/6 with D-
type cyclins to promote activity of the retinoblastoma protein, or mobilizes Cip/Kip 
proteins to block CDK2 and cyclinE/A activity (105). As a small protein inhibitor of 
Mdm2, Arf blocks Mdm2-mediated ubiquitination of p53, thereby promoting p53 
dependent growth suppression (183). While hyperproliferative signals are known to 
induce loss of Arf in animal models (227), the role of Arf loss and implications for 
tumor suppression in humans remains less clear.  
Previous studies investigating the RP-Mdm2-p53 pathway have identified 
cancer-derived mutations that may bypass p53-mediated ribosome biogenesis 
surveillance. Mutation of the zinc finger of Mdm2 disrupts the binding of Rpl5 and 
Rpl11, but not Rpl23, to bypass RP mediated inhibition of Mdm2 (100). In general, 
most cancers ramp up the production of new ribosomes to support elevated levels of 
protein synthesis, so in this context, the RP-Mdm2-p53 pathway could play a more 
prominent role in tumor suppression. Future studies are necessary to assess the 
contribution of this pathway to human cancer. 
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Other mechanisms of p53 inactivation occur in a largely cell type specific 
manner. For instance, human papilloma virus (HPV) types 16 and 18 were 
frequently observed to correlate with cervical cancer and low p53 levels (27). 
Subsequent analysis demonstrated that the HPV E6 oncoprotein could bind to and 
promote the degradation of p53, thus facilitating neoplastic growth (177). A subset of 
breast cancers and neuroblastomas have been postulated to inactivate wild-type 
p53 by nuclear exclusion (123, 125). The cytoplasmic sequestration of the protein 
should prevent targeting of nuclear encoded genes and as a result, promote cell 
proliferation (124). Additional mutations have been reported in ATM kinase (198) 
and Chk2 (3, 207), suggesting disablement of an appropriate p53-mediated 
response to genotoxic stress. 
 
Hep27 is a member of the short chain dehydrogenase/reductase family 
 
Hep27, or Dehydrogenase/Reductase (SDR Family) Member 2 [DHRS2], was 
originally identified as a nuclear protein in the sodium butyrate-treated human 
hepatocellular carcinoma cell line HepG2 (54). Tissue specific expression of Hep27 
is fairly ubiquitous with significant levels reported in the liver and kidneys, and to a 
lesser extent in the breast, bone, and endothelial tissues (68, 156, 179). Further 
characterization of Hep27 revealed a gene with cytogenetic localization to 
chromosome 14q11.2, a region characterized by loss of heterozygosity in a number 
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of different tumor types. Interestingly, deletions at chromosome 14q11.2 have been 
reported with high frequencies in nasopharyngeal carcinoma (23, 133), malignant 
mesothelioma (11), gastrointestinal stromal tumors (42),(30), and metastatic lung 
adenocarcinomas (57). Moreover, Nip3, an E1B 19K/Bcl-2 binding and pro-apoptotic 
gene also maps to chromosome 14q11.2-q12 (22). Taken together, this evidence 
provides a strong clinical basis for chromosome 14q11.2 as a tumor suppressor 
locus.  
Sequence alignment of Hep27 shows conservation across various species, 
with strong similarity to short-chain alcohol dehydrogenase/reductase (SDR) 
enzymes (80). The short-chain alcohol dehydrogenase/reductase (SDR) superfamily 
is a group of primarily NAD/NAD(P) dependent oxidoreductases involved in a host of 
intermediate metabolic processes (80). The family is comprised of over one 
thousand enzymes sharing up to 30% similarity across species as diverse as 
bacteria to humans. Substrate specificity for SDR enzymes ranges from regulatory 
molecules like steroids, prostaglandins, and retinoids, to metabolic components such 
as sugars, alcohols, and other small molecules (201). A common function of the 
SDR family appears to be an intermediate switch for activating or inactivating 
regulatory molecules. In an effort to identify the specific substrate of Hep27, a panel 
of compounds comprised of SDR-specific retinoids, steroids, and carbonyl 
compounds were tested for activity. Screening for Hep27 activity revealed possible 
carbonyl reductase enzymatic function (179). Reactive carbonyl groups are 
frequently found both in endogenous (aldehydes, steroids, prostaglandins, reactive 
lipid peroxidation products) and xenobiotic (pharmacologic drugs, carcinogens, 
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toxicants) compounds (71), often leading to covalent modifications of nucleic acids 
and proteins as well as enhanced oxidative stress when left unchecked. 
Oxidoreductases catalyze the reduction of these potentially damaging compounds to 
facilitate their breakdown and excretion from the cell (146). 
 There is mounting evidence to suggest that oxidoreductases play a role in 
the regulation of p53. NAD(P)H quinone oxidoreductase 1 (NQO1) is a cytosolic 
flavoenzyme reductase responsible for metabolizing quinones. Inhibition of NQO1 by 
dicoumarol, a compound that directly competes with NADH for NQO1 binding, lead 
to enhanced p53 degradation (11). In addition, NQO1 was demonstrated to stabilize 
p53, particularly under conditions of oxidative stress (12). By binding to p53, NQO1 
transiently stabilizes p53 and protects it from 20S proteasomal degradation, a 
process that is both ubiquitin and Mdm2 independent (13,14). The cholesterol 
synthesizing enzyme Seladin-1 (gene name DHCR24) is an FADH dependent 
oxidoreductase that also stabilizes p53. Following conditions of oxidative and 
oncogenic stress, Seladin-1 binds to p53, thereby displacing Mdm2 and leading to 
p53 activation (15). The significance of this information establishes Hep27 as the 
first oxidoreductase capable of regulating Mdm2, indirectly supporting p53 activation. 
 
Mitochondrial genes with extramitochondrial functions 
 The mitochondrial genome encodes a few well-conserved genes necessary 
for respiration, but the vast majority of approximately 2000 mitochondrial proteins 
are encoded by the nuclear genome and selectively imported into the mitochondria 
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following translation in the cytosol (Fig. 1.6) (205). Many of the precursor proteins 
destined for compartmentalization in the mitochondria contain positively charged 20-
60 amino acid mitochondrial targeting signals (MTS) at the N-terminus or internally 
within the protein. Recognition of MTS by the Tom20 receptor facilitates binding and 
directs import of the unfolded protein through the translocase of the outer 
mitochondrial membrane (TOM) complex. From there, energy derived from the 
membrane potential drives proteins through the translocase of the inner 
mitochondrial membrane to be further processed in the matrix or redistributed to the 
inner mitochondrial membrane or intermembrane space. Cleavage of N-terminal 
MTS often occur in the matrix space through an enzymatic process driven by 
mitochondrial processing peptidases (MPP) (55). These enzymes recognize a series 
of cleavage motifs in precursor proteins and mediate the cleavage of the peptides to 
allow for proper folding of mature protein and partitioning to the matrix compartment.      
 The general view held for nuclear encoded mitochondrial proteins is that once 
imported, the mitochondrion sequesters mitochondrial proteins to their respective 
compartments within the organelle. Only in the case of apoptosis, a terminal event, 
are proteins known to exit the mitochondria to perform extramitochondrial functions. 
However, there is evidence to point toward apoptosis-independent 
extramitochondrial localization and function of some mitochondrial proteins. In some 
cases, mitochondrial proteins have been linked to a wide variety of cellular functions 
pertaining to cell growth, antigen presentation, cell mortality, autoimmune diseases, 
and resistance to antimitotic drugs (191). By current estimation, about 92% of 
mitochondrial proteins are known to be exclusively localized to the mitochondria, 
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meaning upwards of 8% may be found in secondary locations (4). One such 
example is Mortalin, a heat shock 70 protein chaperone known to be a critical core 
component in precursor protein import to the mitochondria (212).  Apart from the 
mitochondria, Mortalin has been observed in the endoplasmic reticulum, cytoplasmic 
vesicles, and the cytosol. Interestingly, one reported extramitochondrial function of 
Mortalin is to bind to and suppress the activity of p53 by anchoring the protein in the 
cytoplasm to inhibit nuclear translocation and activity (213).   
 The mechanisms driving non-mitochondrial localization of mitochondrial 
proteins are not well understood, but many hypotheses have been proposed and 
partially substantiated. Differences in transcription, splicing, and translation of mRNA  
have all been suggested to produce altered or truncated protein products that do not 
contain the essential peptide sequence information for mitochondrial import (130). 
Another group has proposed the existence of vesicular trafficking from all three 
compartments of the mitochondria to, in the very least, cytosolic peroxisomes (139). 
These putative mitochondria-derived vesicles have been shown to engulf proteins 
from the outer and inner membranes, as well as both aqueous compartments of the 
mitochondria, and fuse to peroxisomes where the cargo is released. Together, it 
appears that several mechanisms for extramitochondrial targeting of mitochondrial 
proteins exist, and the proteins that are located outside of the mitochondria can 
assume functions not native to their intrinsic mitochondrial roles.   
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Retrograde signaling  
 
 Retrograde signaling, also known as mitochondrial signaling, is a term used 
to broadly describe cellular responses to changes in the functional state of the 
mitochondria (15). This is in contrast to the more well-known anterograde signaling, 
the process involving transfer of information from the nucleus and cytoplasm to the 
mitochondria (Fig. 3). In response to mitochondria-related stress including hypoxia, 
chemical stress, reactive oxygen species, ionophores, or mutagens, the 
mitochondrial membrane potential (∆Ψm) is depleted, thereby triggering release of 
intracellular calcium stores into the cytoplasm. Elevated [Ca2+]c leads to activation of 
calcium- dependent calcineurin, which in turn can promote nuclear gene 
transcription by NFAT and NF-kB transcription factors. These responses are 
generally limited to mild metabolic perturbations requiring adaptive cellular 
adjustments to correct mitochondrial deficiencies or reverse increasing mitochondrial 
dysfunction. 
 The most extreme form of retrograde signaling is induction of programmed 
cell death, or apoptosis. Following apoptotic stimuli, cytochrome c, the sole water 
soluble component of the electron transport chain, is released from the mitochondrial 
intermembrane space into the cytoplasm where it interacts with Apaf-1. This opens 
up the dATP/ATP nucleotide binding domain of Apaf-1 and promotes oligomerization 
to form the apoptosome. Recruitment of procaspase-9 proteins to the apoptosome 
leads to autoactivation of the apoptosome complex and cleavage of executioner 
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caspases such as caspase 3, 6, and 7. Executioner caspases then act on a variety 
of substrates to promote the characteristic morphological changes of apoptosis such 
as chromatin condensation, nucleosomal DNA degradation and formation of 
apoptotic bodies (214). 
            Cytochrome c is accompanied by other apoptogenic proteins that also reside 
within the intermembrane space of the mitochondria. Smac/Diablo, or Second 
mitochondria-derived activator of caspase, is a 25 kDa mitochondrial protein 
released during apoptosis. Smac/Diablo binds to Inhibitor of Apoptosis Proteins 
(IAP’s), which normally serve to keep procaspase-9 in an inactive state, to facilitate 
the release and subsequent autoactivation of procaspase-9 (39). Apoptosis Inducing 
Factor (AIF) is a 57 kDa flavoprotein which shares homology with bacterial 
oxidoreductases. After being released from the mitochondria, AIF translocates to the 
nucleus to induce chromatin condensation and DNA fragmentation independently of 
caspase activation or intrinsic oxidoreductase activity (199). Endonuclease G 
(EndoG), as the name implies, is a 30 kDa nuclease that also translocates to the 
nucleus following apoptosis stimulus and is able to induce large-scale DNA 
fragmentation (98).  
 
c-Myb is a proto-oncogene 
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The proto-oncogene c-Myb was identified as the mammalian homolog of v-
Myb, an oncogene identified in the avian leukemia viruses AMV and E26. c-Myb is a 
member of the Myb family of transcription factors and has been implicated in cellular 
processes of proliferation and differentiation (137). c-Myb is important in 
development as one of a number of genes reported to be essential in maintenance 
and development of definitive hematopoiesis. Transcript levels were initially reported 
to be found at much higher levels in thymic lymphocytes  and cells of the erythroid 
lineage (182). Anti-sense inhibition of c-Myb in normal bone marrow mononuclear 
cells reduced colony formation and expansion in an in vitro assay of heamatopoeisis 
(56). In adult mice, targeted disruption of c-Myb by homologous recombination 
resulted in embryonic lethality at E15 due to gross anemia and defects in a number 
of erythroid lineages, pointing towards the importance of c-Myb in hematopoiesis 
(129). Distinct thresholds of c-Myb activity are proposed to be required for 
appropriate progression through hematopoiesis, where low levels are sufficient for 
progenitor cell expansion, but alter terminal cell differentiation, favoring development 
of macrophage and megakaryocyte over erythroid and lymphoid lineages (46). In 
support of these findings, c-Myb has independently been demonstrated to be 
essential for both T-cell (2, 155) and B-cell (48) development. Conditional c-Myb 
knockout in adult hematopoietic stem cells (HSC) leads to depletion of the HSC pool 
and decreased capacity for self-renewal with significant reduction in all terminal 
lineages, including megakaryocytes. (99). Apart from the bone marrow, c-Myb is 
also important for murine colon development as evidenced by irregular epithelium 
and abnormal crypts in c-Myb knockouts. It is of interest to note that c-Myb gene 
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amplification and over-expression has been documented for a number of leukemia 
subtypes, colorectal cancer, and breast cancer (161), tissues where c-Myb has been 
identified as playing a key role in development. Oncogenic activation of c-Myb is 
generally considered to occur through truncation of the C-terminal regulatory 
domain, and point mutations in the DNA binding domain may confer selective gain-
of-function activity to the protein. However, overexpression of wild-type c-Myb is 
observed in estrogen receptor breast cancer of luminal cell origin (Aaron Thorner, 
personal communication), where the estrogen receptor is known to directly regulate 
c-Myb at a transcriptional level (38).  
Identifying and confirming a common set of c-Myb target genes has remained 
an arduous task with little commonality among the various cell types and 
experimental approaches (9, 95, 161), suggesting that specific targets may be 
context dependent (138). Efforts to identify common c-Myb target genes has 
stratified genes into three general ontologies: those involved with housekeeping 
functions, genes implicated in specific differentiated lineages, and genes involved in 
cell proliferation and survival (161).  
 
Breast cancer: the estrogen paradox 
  
 In the United States, breast cancer is the most common cancer diagnosed 
and the second leading cause of cancer death among women. Conventional 
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parameters for determining prognosis include tumor size and histological grade, 
estrogen and progesterone receptor status, and lymph node status (25). To avoid 
unnecessary treatments that bring undue toxic side effects and financial burden, 
new methods are being developed to predict patient outcomes to different 
therapeutic modalities. DNA microarrays are one method that has been utilized to 
stratify breast cancer into specific subtypes based on their patterns of gene 
expression. Intrinsic gene sets were developed based on significantly different 
patterns of gene expression between tumors versus paired sample controls. Profiling 
based on the intrinsic lists led to classification of luminal epithelial, HER2+/ER-, 
basal-like, and normal breast-like subtypes (157). Each subtype was correlated to 
significant differences in patient outcome, suggesting that hierarchal stratification of 
breast cancer types may not only be useful for understanding the complex biology of 
each type, but ultimately may be a useful tool for prognosis and treatment 
assessment.  
 One defining feature of the luminal epithelial subtype is the presence of the 
estrogen receptor (ER). The ER family of nuclear hormone receptors includes 
thyroid, glucocorticoid, and progesterone receptor which have well-established roles 
in regulation of gene expression (223). Binding of the ER to estrogen ligand 
stimulates dimerization and nuclear translocation of estrogen-ER complex (114) 
which can bind to and promote transcription of downstream target genes involved in 
cell growth and proliferation, inhibition of apoptosis, angiogenesis, as well as genes 
involved in tumor invasion and metastasis (24, 53). Since the general consensus is 
the ER maintains the long-term growth of ER+ cells and is involved in the 
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pathogenesis of this tumor type, a baseline therapy is treatment with selective ER 
modulators (SERM) that antagonize the ER through competitive inhibition of the 
endogenous estrogen ligand. SERMs remain the first line of defense in ER positive 
breast cancer, but development of resistance to the drugs is common and will often 
result in relapse (148).  
 Unlike anti-hormone therapy today which remains the mainstay for treatment 
to attenuate the proliferation of ER positive breast cancers, historical treatment relied 
on the anti-tumor effects of estrogen agonists. During the 1960s, women were 
treated with high doses of the estrogenic compound diethylstilboestrol (84) where it 
was expected that 36% of patients would typically responded favorably (83). 
Moreover, it has been noted that the further a woman is into menopause, the greater 
potential success, in terms of tumor regression, she will have with estrogen therapy 
(62). This is also the case for women who have received, but developed resistance 
to, prolonged anti-estrogen therapy. Administration of estrogen agonists in these 
cases can lead to favorable treatment outcomes by triggering apoptosis of ER 
positive cells. Collectively, these observations suggest that antagonizing the long-
term pro-growth and survival potential of estrogen stimulation actually sensitizes 
mammary cells to the apoptosis inducing effects of estrogen stimulation (176).  
Indeed, antihormone resistance develops in distinct phases of in vivo breast 
cancer models. ER positive MCF7 breast cancer cells that are stimulated by 
estrogen and inhibited by tamoxifen were injected into athymic mice and treated with 
post menopausal doses of estrogen and therapeutic doses of tamoxifen (165). The 
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first phase of resistance occured in less than two years and was defined by the 
capacity of both tamoxifen and estrogen to induce cell growth (149). However, a 
second phase of resistance occurred when mice treated for more than five years of 
antihormone therapy acquired the ability to be stimulated for growth by tamoxifen, 
but inhibited by physiological doses of estrogen (150, 220). This apparent paradox 
between estrogen sustained growth or induction of apoptosis is not well understood, 
but several studies point toward both extrinsic and intrinsic mechanisms of estrogen 
induced apoptosis (112), pathways that are independent and dependent on p53 
respectively.  
Since studies consistently demonstrate that estrogen withdrawal or SERM 
resistance can sensitize ER positive breast cancer cells to the apoptosis inducing 
characteristic of estrogen stimulation, clinical trials have been established to 
investigate this phenomenon as a treatment. To recapitulate studies done in the 
1950s and 1960s, Lonning and colleagues administered diethylstilbestrol to 
postmenopausal women who had become resistant to estrogen deprivation. About 
30% of patients responded favorably with partial or complete remission of disease 
(104). Another study was able to demonstrate that approximately 25% of women 
with advanced metastatic breast cancer who have developed resistance to 
antihormone therapy responded as favorably to low dose (6 mg estradiol/day) as did 
women receiving higher dose (30 mg estradiol/day) therapy, indicating that estrogen 
sensitization had occurred in a subset of patients (45). These studies help to 
reconfirm the potential therapeutic use of estrogen treatment for ER positive breast 
cancer tumors that have acquired resistance to antihormone therapy. In conjunction 
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with appropriate profiling of patient tumors as a diagnostic tool, investigation into the 
pathways that regulate estrogen induced apoptosis in a subset of ER responsive 
tumors may provide an avenue for personalized treatment regimens that could 
respond favorably to estrogen treatment. 
Here we provide a correlation between Hep27 and ER+ luminal breast 
cancer. The data suggests the existence of an ER-c-Myb-Hep27-Mdm2-p53 
functional pathway in the luminal epithelial subtype. Given the potential connection 
of estrogen receptor signaling to p53 activity through c-Myb regulation of Hep27, the 
sensitization of estrogen induced apoptosis by ER inhibition, and the partial 
dependence of some ER positive cells on the apoptosis inducing effects of p53, 
investigation into the contribution of an ER-c-Myb-Hep27-Mdm2-p53 pathway to 
estrogen induced apoptosis could provide a mechanistic link to explain the estrogen 
paradox in a subset of ER+ breast cancers.  
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Figure 1.1 Activation and responses for p53. The p53 stress response regulator 
responds to a variety of stressors to elicit hallmark responses like cell cycle arrest, 
apoptosis, and senescence (red box). Other genetic networks entail genes 
connected to DNA repair, angiogenesis inhibition, and mitochondrial metabolism 
(blue box). 
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Figure 1.2 Mdm2-p53 autoregulatory loop. MDM2 is a direct transcriptional target 
of p53 and promotes the poly-ubiquitination and subsequent degradation of p53, 
forming a negative feedback loop. 
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Figure 1.3 The Ubiquitin-Proteasome System. Ubiquitin molecules require 
enzymatic activation (E1), conjugation (E2), and ligation (E3) to a target substrate 
(X). Poly-ubiquitinated proteins are targeted for degradation by the 26S proteasome. 
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Figure 1.4 Multiple stress signals are transduced through Mdm2 to p53. 
Nucleolar stress triggers ribosomal protein-mediated inhibition of Mdm2, 
hyperproliferative signals induce Arf expression to inhibit Mdm2, and DNA damage 
can activate ATM kinase to phosphorylate Mdm2. Inhibition of the E3 ligase function 
of Mdm2 promotes p53 stability, transactivation of target genes, and induction of cell 
cycle arrest or apoptosis. 
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Figure 1.5 Hep27 protein sequence alignment. Amino acid sequence alignment of 
Hep27 (gene name DHRS2) across multiple eukaryotic species. Yellow: regions of 
identity conserved across all species, Blue: regions of identity conserved across 
some species, Green: regions of homology. Red boxes denote conserved protein 
domains: Rossman Fold GSTXGIG, Catalytic Domain YXXXK 
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Figure 1.6 Model for import of mitochondrial proteins. Nuclear encoded 
mitochondrial precursor proteins containing mitochondrial targeting signals bind to 
the Tom20 receptor, are passed through the translocase of the outer mitochondrial 
membrane complex (TOM), through the translocase of the inner mitochondrial 
membrane complex (TIM), and the N-terminal mitochondrial targeting signal is 
cleaved off by a mitochondrial processing peptidase (MPP). The protein is folded 
into the mature conformation and resides in the respective compartment of the 
mitochondria. 
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Figure 1.7 Nuclear and mitochondrial signaling Anterograde signals involves 
transducing signals from the nucleus to the mitochondria. Conversely, retrograde 
signaling is defined by signals transmitted from the mitochondria to the nucleus. 
  
Chapter 2 
 
Identification and regulation of Hep27 localization 
 
Introduction 
Hep27, or Dehydrogenase/Reductase member 2 (gene name DHRS2), was 
originally identified as a nuclear protein in the sodium butyrate treated human 
hepatocellular carcinoma cell line HepG2 (35, 54). Sequence alignment of Hep27 
reveals considerable evolutionary conservation from plants to humans (179), with 
significant homology to Short-chain alcohol Dehydrogenase/Reductase (SDR) 
enzymes, a superfamily of primarily NAD/NAD(P) dependent oxidoreductases 
involved in a host of intermediate metabolic processes (80). Further characterization 
of Hep27 revealed a gene localized to chromosome 14q11.2 (156), a region 
characterized by high frequency loss of heterozygosity in a number of different tumor 
types including nasopharyngeal carcinoma (23, 133), malignant mesothelioma (11), 
gastrointestinal stromal tumors (30, 42), and metastatic lung adenocarcinomas (57). 
The correlation of Hep27 expression with both inhibition of cell proliferation (54) and 
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cellular quiescence (158), as well as locus specific deletion in a number of cancer 
types, supports the notion that Hep27 has a functional role in promoting growth 
inhibition. 
 The initial localization of Hep27 was reported to be in the nucleus following 
induction by sodium butyrate (35). Follow up analysis revealed that Hep27 could 
also be found in the peri-nuclear region of the cell, but a precise location or organelle 
was not determined. Here we used bioinformatics tools to analyze the primary amino 
acid sequence and predict the localization of Hep27. Hep27 localization to the 
mitochondria matrix was based on the following: 1) amino acids 1-23 are predicted 
to be an N-terminal mitochondrial targeting signal, 2) amino acids 21-25 are a 
conserved R-2 recognition motif for mitochondrial processing peptidase (55), 3) a 
hydropathy plot for Hep27 reveals no predicted transmembrane domains, 4) N-
terminal peptide sequencing of nuclear Hep27 reported the first amino acid of Hep27 
was amino acid 24 (54), suggesting the N-terminal 23 amino acids are cleaved off. 
These findings are confirmed experimentally.   
 
Material and Methods 
Large scale immunoprecipitation 
Wild-type human Mdm2 cDNA sequence was fused to a CMV promoter and 
engineered into adenovirus expressing Mdm2 according to the manufacturer’s 
protocol. U2OS cells were infected with Ad-Mdm2 and allowed to incubate at 37°C 
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and 5% CO2 for approximately 24 hours. Whole cell lysates were harvested in 0.1% 
NP-40 lysis buffer containing 1X protease inhibitor cocktail, 1mM NaVO3, 1mM 
PMSF, and 1 mM DTT. For immunoprecipitation, anti-Mdm2 monoclonal antibody 
2A10 was incubated with whole cell lysates overnight at 4°C. After isolation of 
Mdm2-protein partners with protein-A conjugated beads, the proteins were resolved  
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The gel 
was then silver stained following standard protocols. 
Generation of Hep27 specific antiserum 
For generation of affinity purified polyclonal anti-Hep27 antibody, peptides 
corresponding to amino acid residues 43-57 and 213-227 were used as antigens to 
immunize rabbits. To test for seroconversion, rabbits were bled from the ear vein 
and the sera tested against U2OS whole cell lysates in a Western blot (data not 
shown). Peptide 213-227 provided the greatest specificity and therefore subsequent 
bleeds from this rabbit were used to generate antiserum for use in Western blots and 
immunocytochemistry. 
Cloning of Hep27 
To generate a human Hep27 expression construct, the full length Hep27 
cDNA was amplified by reverse-transcriptase Polymerase Chain Reaction (PCR) 
from a HeLa cell mRNA library using primers F1, 5’-ATATGGATCCTTCTGTCAG 
CAGTTGCCCGGGGC-3’ and R1, 5’-GCCGTCTAGAGGAGAATGCCGAAGCGTTT 
TTCTT -3’. The PCR product was cloned into the pcDNA3.1 parental vector using 
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BamHI and XbaI sites in the multiple cloning site. Expression was confirmed by 
Western analysis (data not shown).  
 
Molecular Constructs 
pcDNA3-Flag vector was used to construct Hep27 full length and DelN24. 
pcDNA3-Myc was used to construct N-terminal tagged Hep27 and Mdm2 truncation 
mutants. pEGFP-NI (Clontech) was used to generate HepMTS-GFP. 
Cell culture and transfection 
U2OS cell line was maintained in Dulbecco’s modified eagles medium 
supplemented with 10% fetal bovine serum, L-glutamine, 100 U/ml penicillin and 100 
ug/ml streptomycin at 5% CO2 in a humidified chamber. Cell transfections were carried 
out with Fugene 6 (Roche), Fugene HD (Roche), or Effectene (Qiagen) reagents. 
Sodium butyrate was supplied from Sigma. 
Biochemical fractionation 
A differential detergent fractionation (DDF) protocol (162) has been optimized to 
address compartment partitioning across the nucleus, cytosol, and mitochondria. Cells 
were first subjected to digitonin treatment, which permeabilizes the plasma membrane 
and facilitates extraction of soluble, cystosolic proteins. Next, a low concentration of the 
nonionic detergent Triton X-100 was used to solubilize organelle lipid membranes to 
collect the majority of mitochondrial proteins while simultaneously maintaining the 
integrity of the nuclear membrane. The last phase involved purification of intact nuclei 
over a sucrose gradient, followed by brief sonication to extract nuclear proteins. Ten 
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percent of the total cell volume was used to extract total protein lysates using sodium 
dodecyl sulfate lysis buffer, followed by physical shearing through a 27G needle to 
break up the chromatin and facilitate solubilization of chromatin bound proteins. 
Immunoflourescence imaging 
Monolayer cells were fixed with formaldehyde, permeabilized by 0.2% triton-
X100 and targeted with primary anti-Hep27 or anti-Flag M2 antibody. Goat anti-
rabbit rhodamine red-, Cy2-, fluorescein isothiocyanate-, and 7-amino-4-
methylcoumarin-3-acetic acid (AMCA)-conjugated secondary antibodies were 
purchased commercially (Jackson ImmunoResearch Laboratories). Mitotracker Red 
CMXRos (Invitrogen) was used for mitochondrial staining, and DAPI (4’,6-diamidino-
2-phenylindole) was used for nuclear demarcation. Immunostained cells were 
analyzed using an Olympus IX-81 microscope fitted with a SPOT camera and 
software. 
Transmission electron microscopy 
Cells grown on chamberslides were fixed with 4% paraformaldehyde in 0.15M 
sodium phosphate, pH 7.4, for 1 hour.   Using a pre-embedding immunogold/silver 
staining protocol(221), cells were incubated in a 1:50 dilution of rabbit anti-Hep27, 
followed by the secondary antibody incubation in goat anti-rabbit IgG 0.8nm 
immunogold (Aurion, Electron Microscopy Sciences).  After silver enhancement, the 
cells were processed and embedded Polybed 812 epoxy resin (Polysciences, Inc., 
Warrington, PA).  70nm ultrathin sections were cut, mounted on copper grids, and post-
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stained with 4% uranyl acetate and Reynolds’ lead citrate.  Sections were observed 
using a LEO EM-910 transmission electron microscope operating at 80kV (LEO 
Electron Microscopy, Thornwood, NY) and images were taken using a Gatan Orius 
SC1000 CCD camera with Digital Micrograph 3.11.0 (Gatan, Inc., Pleasanton, CA). 
Antibodies 
The following antibodies were commercially purchased: mouse anti-Actin 
(Neomarkers), rabbit anti-GRP75 H-155 (Santa Cruz), rabbit anti-Histone H3 9715 
(Cell Signaling), mouse anti-Flag M2 (Sigma). Rabbit anti-Myc was kindly provided 
by Yue Xiong, Ph.D..  
Western blot analysis 
Cells were washed with PBS, lysed in Mammalian Protein Extraction Reagent 
(Thermo Scientific) supplemented  with 1X protease inhibitor cocktail, 1mM NaVO3, 
1mM PMSF, and 1 mM DTT. 5X Laemmli sample buffer was added to cell lysates, 
resolved on 10% SDS-PAGE, and transferred to Immobilon PVDF membranes. 
Membranes were blocked in 10% nonfat dry milk in TBS-Tween-20 and probed with 
appropriate primary antibodies, followed by anti-mouse or -rabbit IgG-horseradish 
peroxidase (HRP)-conjugated secondary antibody (Amersham Biosciences). 
Membranes were incubated in SuperSignal West Dura Extended Duration substrate 
or SuperSignal West Pico substrate (Thermo Scientific) and the signal developed on 
HyBlot CL autoradiography film (Denville Scientific Inc.). 
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Results 
Identification of Hep27 
In an effort to identify novel Mdm2 binding partners, a large-scale 
immunoprecipitation (IP) experiment was performed using Mdm2 as bait in the 
osteosarcoma U2OS cell line. An adenovirus construct expressing wild-type Mdm2 
was used to infect U2OS cells. The IP was resolved by SDS-PAGE, silver stained, 
and bands of interest not found in the adenovirus GFP control sample were 
subjected to mass spectrometry protein microsequencing (Fig. 2.1A). The large 
ribosomal proteins L5, L11, and L23, previously reported to bind to Mdm2 through 
IP, also appeared in this pull down. A fourth prominent band, migrating just below 
the IgG light chain (IgG-L), with an apparent molecular weight of 24 kDa was 
identified as Hep27.  
Hep27 was originally described as a predicted 27 kDa protein residing within 
the nucleus of HepG2 cells following treatment with the histone deacetylase 
inhibitor, sodium butyrate; a drug that induces a reversible G1 cell cycle arrest. 
Further analysis reporting the full coding sequence of Hep27 described a protein 
with 280 amino acids (54), that could be detected as two different bands by western 
blot (156). The recombinant cDNA sequence predicts a protein of 280 amino acids 
with a predicted mass of 29.9 kDa. However, initial N-terminal peptide sequencing of 
purified Hep27 revealed a truncated protein beginning at Ser24 with a predicted 
mass of 27.3 kDa. The truncated form of Hep27 is the predominant band in most cell 
types and tissues we, and others, have surveyed (data not shown). It is also the 
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form that was detected in our Mdm2 screen in U2OS cells migrating just below the 
25 kDa marker. We consistently detect Hep27 at this position in HepG2, U2OS, and 
MCF7 cells; three cell lines expressing relatively robust levels of Hep27. Therefore, 
we conclude that the 24kDa Hep27 identified by mass spectrometry in our 
experiments is Hep27 (isoform 2), and reflects the same protein reported in previous 
literature. 
 
Hep27 is predominantly a mitochondrial protein 
Previous reports have described Hep27 as a nuclear protein with prominent 
cytoplasmic localization (54). However, computational algorithms predicted 
mitochondrial localization (26, 47). To gain direct insight into Hep27 localization, a 
polyclonal antibody was raised against a short peptide near the C-terminus 
(VVPGIIKTDFSKVFH). The fluorescent immunostaining pattern of Hep27 exhibited 
striated perinuclear staining, consistent with possible mitochondrial localization (Fig. 
2.1B). To verify this possibility, the cells were simultaneously probed with Mitotracker 
Red CMXRos, a marker selective for mitochondrial staining. The merged image 
demonstrates that endogenous Hep27 co-localizes with mitochondria in U2OS cells 
(Fig. 2.1B). 
To further solidify Hep27 as a mitochondrial protein, a differential detergent 
fractionation (DDF) procedure (162) was optimized to partition out mitochondrial 
proteins. Three independent replicates of DDF performed on endogenous protein in 
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U2OS cells demonstrate Hep27 accumulating with Heat shock protein 70 (Hsp70) in 
the mitochondrial fraction and not with the cytoplasmic fraction (Fig. 2.1C).  
Immunogold labeling of endogenous Hep27 in U2OS cells for visualization by 
transmission electron microscopy (TEM) illustrates a staining pattern enriched within 
mitochondria with gold particle distribution appearing randomly throughout the 
organelle (Fig. 2.1D). Together the evidence supports the predominant localization 
of Hep27 in the mitochondria.  
 
Hep27 contains an N-terminal mitochondrial targeting signal 
In general, nuclear-derived gene products destined for the mitochondria must 
undergo import via the translocase of the outer membrane (Tom) complex 
embedded in the mitochondrial outer membrane (204). The Tom20 import receptor 
facilitates import of proteins containing mitochondrial targeting signals (MTS) (159). 
Initial reports of Hep27 described a protein beginning at Ser24, consistent with 
amino acids 1-23 comprising a putative MTS that is later cleaved during processing 
(Fig. 2.2A).  
To examine the role of this possible MTS in Hep27, we created an N-terminal 
deletion mutant removing the first 24 amino acids (Hep27-DelN24-Flag) and 
assessed mitochondrial exclusion by immunofluorescence staining. Full length 
Hep27 retains predominantly mitochondrial localization, whereas Hep27-DelN24 
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exhibits no obvious perinuclear staining and does not overlay with the mitochondrial 
marker (Fig. 2.2B).  
To further assess the functional nature of the MTS, the DNA sequence 
corresponding to amino acids 1-24 of Hep27 was cloned into pEGFP-N1 to generate 
HepMTS-GFP; a fusion protein containing the potential MTS of Hep27 at the N-
terminus of EGFP. Control GFP expression in U2OS cells is distributed equally 
throughout the cytosol and nucleus of the cell, with no visible entry into the 
mitochondria (Fig. 2.2C). However, HepMTS-GFP exhibits a similar perinuclear 
pattern to endogenous Hep27 and co-localizes well with mitotracker staining, 
indicating efficient import of HepMTS-GFP to the mitochondria. 
 
Hep27 is a mitochondrial matrix protein 
Mitochondrial proteins most often contain amino terminal mitochondrial 
targeting presequences that stimulate import into the mitochondrion. The Tom 
complex is a multi-subunit complex consisting of receptor proteins that recognize 
targeting presequences and thread the pre-proteins through an aqueous channel 
into the intermembrane space. The “translocase of the inner membrane” (Tim23) 
complex recognizes the import signal, cleaves the signal to generate the mature 
protein, and partitions the mature product to a final destination in the intermembrane 
space, the inner membrane, or the mitochondrial matrix (Fig. 1.6) (204). 
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Overexpression of an N-terminal Myc-tagged Hep27 by adenovirus infection 
of WI38 cells, a cell line not expressing Hep27, resulted in a cleavage product that 
was specific for the anti-Hep27 antibody and had a molecular mass of 24 kDa, the 
precise size of endogenously detected Hep27 (Fig. 2.3A).This is a likely indication 
that the full length Hep27 is processed during import into the mitochondria and the 
amino terminal Myc tag, by virtue of being located on the N-terminus, partially masks 
the mitochondrial import presequence.  
Once imported into the matrix space, the MTS is cleaved off to generate the 
mature product of Hep27. Cleavage was confirmed by analyzing the HepMTS-GFP 
fusion construct expression patterns. Expression of GFP alone produced the 
expected single banding pattern observed by western blot. However, the HepMTS-
GFP fusion constructs produced a double banding pattern, indicating that the full 
length precursor protein was cleaving off the mitochondrial targeting signal in the 
matrix compartment to produce the mature, native sized, GFP protein (Fig. 2.3B). 
Mutation of the first methionine in the GFP open reading frame had no effect on the 
double banding pattern, indicating that the lower GFP band was not the product of 
aberrant translation. 
Finally, a higher magnification immunogold labeled micrograph of U2OS 
shows a transverse cross-section of a mitochondrion with Hep27 labeling randomly 
distributed throughout the matrix space and  little concentration to the 
intermembrane space or membrane regions (Fig. 2.3C). Together, with direct 
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mitochondrial import and cleavage of a mitochondrial targeting signal, the evidence 
supports the predominant localization of Hep27 in the mitochondrial matrix.  
 
Mature Hep27 is partially localized to the nucleus 
A number of mitochondrial proteins, including Hsp60 and p32, have been 
reported to be partially localized to extra-mitochondrial locations to perform non-
mitochondrial functions (190). Since Hep27 was initially reported as a nuclear 
protein (54), we assessed possible nuclear localization of Hep27 by visualizing 
endogenous Hep27 in U2OS via TEM. There is detectable nuclear distribution of 
gold particle labeled Hep27 within the nuclei (Fig. 2.4A).  
These findings are corroborated by subcellular fractionation of U2OS cells 
(Fig. 2.4B) where the majority of Hep27 is found within the mitochondria as 
expected, but a minor fraction accumulates within the nucleus. These findings 
together provide evidence that, once processed in the mitochondrial matrix, a minor 
fraction of Hep27 translocates from the mitochondria to the nucleus. It should be 
noted that while Hep27 is abundantly expressed in U2OS cells, processing of Hep27 
to the mature form can only occur in the mitochondrial matrix, indicating that the 
minor fraction of Hep27 located within the nucleus must be translocated from the 
mitochondria to the nucleus.  
 
Discussion 
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Like many mitochondrial proteins, synthesis of nuclear encoded Hep27 
occurs in the cytoplasm, followed by translocation and import into the mitochondrial 
matrix where cleavage of the mitochondrial targeting signal occurs to generate 
mature Hep27. The mature protein accumulates primarily in the mitochondria, 
potentially performing “housekeeping” functions on unknown substrates within the 
matrix space. Previous screening for potential mitochondrial substrates of Hep27 
suggested an NADPH-dependent carbonyl reductase function (179). Further 
experimentation is necessary to determine the precise mitochondrial function of 
Hep27. 
As a mitochondrial matrix protein, it seems counterintuitive that a protein with 
native functions in the mitochondria could impart functions elsewhere in the cell. 
However, it is estimated that 10% or more of mitochondrial proteins exhibit dual 
subcellular locations (151, 187) and there is mounting evidence to support extra-
mitochondrial functions for nuclear encoded mitochondrial matrix proteins (190). 
Much like Hep27, Hsp60 contains an N-terminal mitochondrial targeting signal that 
directs newly synthesized Hsp60 to the mitochondrial matrix where the signal 
peptide undergoes cleavage to generate the mature form of the protein. This mature 
form of Hsp60 has been documented to localize in the endoplasmic reticulum, 
plasma membrane, and peroxisomes, where it may function as a chaperone for non-
mitochondrial proteins (85, 189). Mitochondrial Hsp70 is yet another protein that is 
localized to the cytoplasm where  it contributes to cellular senescence (211). Given 
the critical importance of mitochondria as dynamic integrators of signaling events 
related to cell proliferation, nutrient sensing, energy, and metabolism (59, 171), it will 
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be interesting to explore other possible mitochondrial matrix proteins that may have 
extramitochondrial localization and function. 
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Figure 2.1 Hep27 is a mitochondrial protein. (A) U2OS cells infected by 
adenovirus expressing control GFP or Mdm2 for 24 hours were immunoprecipitated 
with α-Mdm2 2A10 antibody and resolved by SDS-PAGE. Hep27 was identified by 
mass spectrometry protein microsequencing analysis. (B) Immunoflourescence 
imaging of endogenous Hep27. U2OS cells were probed with α-Hep27 antibody, 
Mitotracker CMXRos, and DAPI. (C) Differential detergent fractionation performed in 
triplicate in U2OS cells to fractionate endogenous Hep27. Hsp70 is a mitochondrial 
control, actin is a cytosolic control, and Histone H3 a nuclear control. (D) 
Transmission electron microscopy of endogenous Hep27 in U2OS cells. U2OS 
monolayers were fixed, probed with control IgG antibody (left) or α-Hep27 primary 
antibody (right), and visualized by TEM. 
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Figure 2.2 Hep27 contains an N-terminal mitochondrial targeting signal. (A) 
Schematic illustrating the full length and mature forms of Hep27. The mitochondrial 
targeting signal sequence, comprised of amino acids 1-23,  is shown. (B) Expression 
constructs expressing full length C-terminal Flag-tagged Hep27 or Hep27-DelN24 
were transfected into U2OS cells. α-Flag M2 antibody was used to detect the flag-
tagged protein. Mitotracker CMXRos was used to visualize mitochondria, and DAPI 
was used for nuclear staining. (C) Expression constructs expressing control GFP or 
HepMTS-GFP fusion protein were transfected into U2OS cells. Mitotracker CMXRos 
was used to visualize the mitochondria and DAPI used for nuclear staining. 
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Figure 2.3 Hep27 is localized to the matrix compartment of the mitochondria. 
(A) Adenovirus constructs expressing control GFP, or N-terminal Myc-tagged 
Hep27, were transduced into H1299 cells for 24 hours. Western blot shows 
detection of the same blot by α-Myc and α-Hep27. The higher migrating band 
reflects the Myc-tagged fusion protein, whereas the lower band reflects processed 
mature Hep27 that has had the Myc-tagged mitochondrial targeting signal cleaved 
off. (B) Expression constructs expressing control GFP, Hep27MTS-GFP, or 
Hep27MTS-GFP M35A were transfected into U2OS cells. GFP bands were detected 
by α-GFP antibody. Lanes 1-3 depict individual clones of Hep27MTS-GFP (M35A). 
The higher band reflects the fusion protein, whereas the lower band reflects fusion 
protein that has been processed to native GFP by removal of the mitochondrial 
targeting signal. HepMTS-GFP (M35A) missense mutants demonstrate that the 
lower migrating GFP band is not a result of aberrant translation at the first 
methionine of the GFP open reading frame. (C) Endogenous Hep27 staining is 
distributed throughout the mitochondrial matrix. As in Fig. 1F, U2OS cells were 
probed with α-Hep27 primary antibody and visualized at a higher magnification by 
TEM. 
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Figure 2.4 Hep27 partially localizes to the nucleus. (A) U2OS cell monolayers 
were fixed and probed for endogenous Hep27 with α-Hep27 antibody. Arrows 
denote gold bead labeled Hep27 as detected by TEM. (B) Differential detergent 
fractionation was used to fractionate endogenous total (Tot) Hep27 from U2OS cells 
into cytosolic (Cyto), mitochondrial (Mito), and nuclear (Nuc) compartments for 
detection by western blot. Actin, Hsp70, and Histone H3 were used as cytosolic, 
mitochondrial, and nuclear controls respectively. 
 
 
 
 
  
Chapter 3 
 
Hep27 is an Mdm2 binding partner that regulates p53 
stability 
  
Introduction 
Post-translational inhibition of Mdm2 is an important means of modulating p53 
function in response to a number of cellular insults including nucleolar and mitogenic 
stress. The intermediate mediators of these Mdm2 regulatory pathways include the 
large ribosomal proteins Rpl5, Rpl11, and Rpl23, as well as the tumor suppressor 
ARF (Figure 3.1). These basic proteins all bind to a region around the central 
domain of Mdm2 comprised of the acidic domain and zinc finger. The primary 
reported function of Mdm2 small binding proteins is to inhibit the E3 ligase activity 
and promote p32 stabilization. All of these known small binding partners are 
localized primarily to the nucleolus, maintaining close proximity to Mdm2. Here we 
demonstrate that mitochondrial protein Hep27, another small basic protein, can bind 
to the acidic domain of Mdm2 and promote p53 stabilization.  
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Materials and Methods 
Antibodies and reagents 
The following antibodies were commercially purchased: mouse anti-Mdm2 
4B11, 2A10, and SMP14 (UNC Tissue Culture and Molecular Biology Support 
Facility), mouse anti-Actin (Neomarkers), mouse anti-p53 DO.1 (Neomarkers), 
mouse anti-Flag M2 (Sigma). Rabbit anti-p21 was kindly provided by Yue Xiong, 
Ph.D.. Hep27 antibody was generated as stated in chapter 2.  
Molecular constructs 
To generate a human Hep27 expression construct, the full length Hep27 
cDNA (Open Biosystems) was amplified by Polymerase Chain Reaction (PCR) and 
cloned into the pcDNA3 expression vector (Invitrogen). pcDNA3-Flag vector was 
used to construct Hep27 full length and DelN24. The ADEASY XL system 
(Stratagene) was used for creating adenovirus.  DNA sequences were subcloned 
into pShuttle-CMV, recombined with pADEASY-1 vector, and transfected into 293 
QBT cells to generate adenovirus. 
Cell culture and transfection 
U2OS, H1299, MCF-7, HepG2 and WI-38 cell lines were maintained in 
Dulbecco’s modified eagles medium supplemented with 10% fetal bovine serum, L-
glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin at 5% CO2 in a humidified 
chamber. Cell transfections were carried out with Fugene 6 (Roche), Fugene HD 
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(Roche), or Effectene (Qiagen) reagents. MG132 proteasome inhibitor was 
purchased from Sigma. 
Immunoprecipitations 
Cells were infected transfected with indicated constructs, or untreated for 
endogenous protein IP, and allowed to incubate at 37°C and 5% CO2 for 
approximately 24 hours. Whole cell lysates were harvested in 0.1% NP-40 lysis 
buffer containing 1X protease inhibitor cocktail, 1mM NaVO3, 1mM PMSF, and 1 mM 
DTT. For immunoprecipitation, the indicated antibodies were incubated with whole 
cell lysates overnight at 4°C. After isolation of specified antibody with protein-A 
conjugated beads, the proteins were resolved  by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The gel was then immunoblotted 
with the indicated antibodies. 
RNAi    
 Oligofectamine reagent (Invitrogen) was used for transfection of RNAi oligos. 
The Hep27 sequences (Invitrogen) targeting the 3’ end of the coding sequence 
were: RNAi 1 5’- GGAACAUCAUCAGCUGCAGAGGAUU, RNAi 2 5’- 
CCUGGUCUCUUCCAUUGCAGCU UAU. 
Western blot analysis 
Cells were washed with PBS, lysed in Mammalian Protein Extraction Reagent 
(Thermo Scientific) supplemented  with 1X protease inhibitor cocktail, 1mM NaVO3, 
1mM PMSF, and 1 mM DTT. 5X Laemmli sample buffer was added to equivalent 
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amounts of cellular lysates which were then resolved on 10% SDS-PAGE and 
transferred to Immobilon PVDF membranes. Membranes were blocked in 10% 
nonfat dry milk in TBS-Tween-20 and probed with appropriate primary antibodies, 
followed by anti-mouse or -rabbit IgG-horseradish peroxidase (HRP)-conjugated 
secondary antibody (Amersham Biosciences). Membranes were then incubated in 
SuperSignal West Dura Extended Duration substrate or SuperSignal West Pico 
substrate (Thermo Scientific) and the signal developed on HyBlot CL 
autoradiography film (Denville Scientific Inc.). 
Densitometry 
UN-SCAN-IT gel (V 5.1) scanning software (Silk Scientific) was used to digitize all 
indicated blots. The ratio of p53:Actin was calculated per sample and the ratios then 
compared to the control ratio to determine fold differences. 
 
Results 
Hep27 is an Mdm2 binding partner 
Given that Hep27 was pulled out of an Mdm2 screen for binding partners, we 
sought to determine the validity of this binding interaction. A coupled 
transcription/translation system was used to synthesize 35S-Methionine labeled 
human Mdm2 and Hep27-Flag. Immunoprecipitations were performed using a 
monoclonal mouse antibody to Mdm2 (4B11) or an anti-Flag monoclonal antibody. 
Mdm2 and Hep27 can bind in reciprocal fashion in a cell-free system (Fig. 3.2A).  
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Further investigation into binding dynamics of Mdm2 and Hep27, utilized 
constructs expressing Mdm2 and Myc-tagged Hep27 which were co-expressed by 
transient transfection in U2OS cells (Fig. 3.2B). After 24 hours of incubation, cell 
lysates were immunoprecipitated using mouse monoclonal antibodies targeting 
either Mdm2 or Hep27. This experiment illustrates reciprocal binding of ectopic 
Hep27 to Mdm2.  
We then sought to determine if endogenous Mdm2 could bind to endogenous 
Hep27. HepG2 cells, which express relatively abundant levels of Hep27, were grown 
to near confluence and either treated with the proteasome inhibitor MG132 for 6 
hours to facilitate protein accumulation or left untreated. Cell lysates were harvested 
and subjected to overnight immunoprecipitation of endogenous Mdm2 using three 
different mouse monoclonal antibodies (4B11, 2A10, SMP14), as well as an anti-
Myc antibody (9E10) for use as a negative control (Fig. 3.2C). Mdm2, whether in the 
presence or absence of accumulated protein, can pull down Hep27, indicating that 
Mdm2 and Hep27 interact in vivo. 
 
Hep27 binding maps to the acidic domain of Mdm2 
The region of Mdm2 targeted by Hep27 binding was then examined. To 
accomplish this, endogenous Hep27 in U2OS cells was assessed for Mdm2 binding 
using a series of N- and C-terminal Myc-tagged Mdm2 deletion mutants (Fig. 3.3). 
The constructs were transiently transfected into U2OS cells, incubated for 24 hours, 
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and IP’s were performed using a mouse anti-Myc monoclonal antibody. Ribosomal 
protein L11 (Rpl11), a protein previously reported to bind amino acids 284-374 of 
Mdm2 (225), was used as a binding control. The binding of Hep27 to Mdm2 deletion 
mutants closely resembled that of Rpl11 binding, with negligible binding to Mdm2 
(295-491) and Mdm2 (1-199). Hep27 binds to all constructs containing amino acids 
200-294 of Mdm2, the region containing the acidic domain of Mdm2. 
 
Hep27 binding to Mdm2 promotes p53 stability 
There are a number of small, basic proteins that bind to Mdm2 in the central 
acidic domain and trigger p53 stabilization. These include the large ribosomal 
proteins L5, L11, and L23, as well as p14ARF. All of these proteins exhibit tumor 
suppressor function by acting as negative regulators of Mdm2, indirectly supporting 
p53 stabilization, accumulation, and subsequent transactivation. Initial experiments 
did not support a role for Hep27 as a substrate for Mdm2 mediated ubiquitination 
and degradation (Fig. 3.3).                           
 Consistent with other Mdm2 binding proteins such as p14ARF and Rpl11, 
Hep27 is also a basic protein (pI of 8.9 in the mature form) that binds to the central 
domain of Mdm2; therefore we investigated the possibility that Hep27 could induce 
p53 accumulation and transactivation. To this end, CMV-driven constructs 
expressing Mdm2, p53, and C-terminal Flag-tagged Hep27 and Hep27-DelN24 were 
transfected into the p53 null cell line H1299 (Fig. 3.4A). Introduction of Hep27 and 
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Hep27-DelN24 with Mdm2 alone results in modestly enhanced levels of Mdm2. Co-
expression of Hep27 or Hep27-DelN24 leads to significant p53 stabilization and 
subsequent transcriptional activation of both p21 and Mdm2.  
To verify that Hep27 can stabilize endogenous p53 in a physiological setting, 
where ratios of Mdm2 and p53 are in a stoichiometric balance, adenovirus 
expressing C-terminal Flag tagged Hep27 was used to infect WI38 cells, normal 
human lung fibroblasts containing wild type p53 and no detectable Hep27 
expression (Fig. 3.4B). Increased levels of Hep27 resulted in p53 protein 
accumulation and induced p53-mediated transactivation of p21 and Mdm2.   
Hep27 is transported to and processed in the mitochondria where it 
predominantly resides. To determine if the endogenous p53 stabilizing effects of 
Hep27 occur outside of the mitochondria, Hep27-DelN24-Flag, a mutant lacking the 
mitochondrial targeting signal, was ectopically expressed in MCF7 cells (Fig. 3.4C). 
Protein levels of p53 increased in a dose dependent fashion by Hep27-DelN24 
expression, suggesting that the interaction likely occurs in the nucleus.  
Since over-expression of Hep27 was able to stabilize p53, we next 
investigated whether reducing Hep27 protein levels could reduce p53 levels in non-
stressed cells. Knocking down endogenous levels of Hep27 with two different RNAi 
sequences in both MCF7 and U2OS cells reduced basal levels of p53 (Fig. 3.5), 
suggesting that endogenous Hep27 expression in the absence of stress is important 
to maintain basal p53 levels.  
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Elevation of basal p53 levels by Hep27 may have important implications in 
terms of priming cells for apoptosis or enhancing p53 activity under physiological 
stress conditions. In summary, these results indicate that Hep27 binding to Mdm2 
can stabilize p53 levels in a dose-dependent manner and induce p53 transactivation 
of downstream target genes. 
 
Discussion 
Post-translational inhibition of Mdm2 is an important means of modulating p53 
function in response to a number of cellular insults including nucleolar and mitogenic 
stress. The intermediate mediators of these Mdm2 regulatory pathways include the 
large ribosomal proteins L5, L11, and L23, as well as the tumor suppressor p14ARF. 
All of these small basic proteins are localized primarily to the nucleolus, maintaining 
close proximity to Mdm2. Here we demonstrate that mitochondrial protein Hep27, 
another small basic protein, can bind to Mdm2 in the central acidic domain and 
promote p53 stabilization and transactivation of downstream target genes. 
Interestingly, knockdown of endogenous Hep27 in tumor cell lines results in 
an overall decrease in p53 stability. The surveyed tumor types where Hep27 is 
expressed also retain wild-type p53. It is unclear if the correlation of Hep27 
expression with wild-type p53 represents a conserved phenomenon or is a result of 
the limited sample size of our survey. Mitochondrial Hep27-mediated stabilization of 
p53 may suggest that mitochondrial crosstalk to the nucleus modulates p53 
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metabolic functions to promote overall mitochondrial function. This hypothesis is 
discussed at greater length in chapter 6.  
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Figure 3.1 Schematic of Mdm2 binding partners. ARF is a highly basic nucleolar 
protein (pI 12.1) that is a potent inhibit of Mdm2 function. The ribosomal proteins L5, 
L11, and L23 are all modestly basic proteins that bind to the central acidic core of 
Mdm2. Hep27 has a pI of 9.1 (precursor form) or 8.9 (mature form). The mature form 
of Hep27 was mapped to bind to amino acids 200-294 of Mdm2 (Fig. 3.3), consistent 
with inhibitory regulatory function for Mdm2 small binding proteins. 
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Figure 3.2 Hep27 binds to Mdm2. (A) TNT quick-coupled transcription/translation 
system was used to synthesize 35S-Methionine labeled Mdm2 and Hep27-Flag. 
Reciprocal immunoprecipitations with α-Mdm2 2A10 or α-Flag M2 were detected by 
western blot. Loading control shows 10% of starting material. (B) Adenovirus 
constructs expressing Mdm2 or Myc tagged Hep27 were transduced into H1299 
cells. Reciprocal immunoprecipitations with α-Mdm2 2A10 or α-Hep27 were 
detected by western blot. Loading control shows 10% of starting material. (C) 
Endogenous Mdm2 and Hep27 were immunoprecipitated from HepG2 cells using 
control α-Myc 9E10 antibody, or three different Mdm2 antibodies: 4B11, 2A10, and 
SMP14. Cells were incubated in the presence or absence of the proteasome 
inhibitor, MG132, for six hours prior to IP. Loading shows 10% of starting material. 
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Figure 3.3 Hep27 binds to the central region of Mdm2. Expression constructs 
expressing Myc tagged wild type and C- or N-terminal Mdm2 truncation mutants 
were transfected into U2OS cells. Mdm2 constructs were immunoprecipitated with α-
Myc 9E10 antibody and proteins detected by western blot. Endogenous Rpl11 was 
used as an Mdm2 binding control. Loading shows 10% of starting material. 
Schematic (bottom) summarizes experimental evidence and narrows Hep27 binding 
to Mdm2 amino acids 200-294. 
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Figure 3.4 Hep27 binding to Mdm2 results in p53 stability and transactivation. 
(A) Expression constructs expressing Mdm2, p53, Hep27, and Hep27-DelN24 were 
co-expressed in H1299 cells by transient transfection for 24 hours and indicated 
proteins detected by western blot. (B) Adenovirus construct expressing Hep27-Flag 
was transduced into WI38 primary fibroblasts for 24 hours and indicated proteins 
detected by western blot. (C) Hep27-DelN24 was transiently expressed in MCF7 
cells for 24 hours and indicated proteins detected by western blot. 
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Figure 3.5 Hep27 promotes stability of endogenous p53. Two independent oligos 
were used to knockdown Hep27 in MCF7 and U2OS cells. Endogenous Hep27 and 
p53 were assessed by western blot.  
 
 
 
 
 
  
Chapter 4 
 
Role of c-Myb in Hep27 regulation and p53 stability 
 
Introduction 
The proto-oncogene c-Myb was identified as the mammalian homolog of v-
Myb, an oncogene identified in the avian leukemia viruses AMV and E26. c-Myb is a 
member of the Myb family of transcription factors and has been implicated in cellular 
processes of proliferation and differentiation (137). Oncogenic activation of c-Myb is 
generally considered to occur through truncation of the C-terminal regulatory 
domain, and point mutations in the DNA binding domain may confer selective gain-
of-function activity to the protein. However, overexpression of wild-type c-Myb is 
observed in estrogen receptor positive breast cancer of luminal cell origin (Aaron 
Thorner, personal communication), where the estrogen receptor is known to directly 
regulate c-Myb at a transcriptional level (38).  
Identifying and confirming a common set of c-Myb target genes has remained 
an arduous task with little commonality among the various cell types and 
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experimental approaches (9, 95, 161), suggesting that specific targets may be 
context dependent (138). Efforts to identify common c-Myb target genes has 
stratified genes into three general ontologies: those involved with housekeeping 
functions, genes implicated in specific differentiated lineages, and genes involved in 
cell proliferation and survival (161). Previous studies investigating gene expression 
patterns of c-Myb by microarray analysis suggested the possibility of Hep27 as a 
downstream target gene. Here we demonstrate how c-Myb can induce Hep27 
expression. 
 
Materials and Methods 
Antibodies and reagents 
The following antibodies were commercially purchased: mouse anti-Actin 
(Neomarkers), mouse anti-p53 DO.1 (Neomarkers), rabbit anti-c-Myb 45150, rabbit 
anti-GRP75 H-155 (Santa Cruz), rabbit anti-Histone H3 9715 (Cell Signaling). Rabbit 
anti-p21 was kindly provided by Yue Xiong, Ph.D. Hep27 antibody was generated as 
stated in chapter 2.  
Molecular constructs 
pCMV-Sport6-c-Myb mammalian expression plasmid was purchased (Open 
Biosystems). Primers used to amplify regions of interest from U2OS genomic DNA 
were: AB (MybLucP1F 5’-AGAGGTGAAGCCGGCTGGGCTTC, MybLucP1R 5’-
GCTGCCGGCTC AGGCAGCCTG) and CD (MybLucENF 5’-ACTCATTGC 
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GAGGGTCCGTGG, MybLucENR 5’-CTGGGGGAAAGAATCAATTTCACTTATC). 
PCR fragments were subcloned into pGL3-Basic Luciferase reporter plasmid. 
Cell culture and transfection 
H1299, MCF-7, and WI-38 cell lines were maintained in Dulbecco’s modified 
eagles medium supplemented with 10% fetal bovine serum, L-glutamine, 100 U/ml 
penicillin and 100 ug/ml streptomycin at 5% CO2 in a humidified chamber. Cell 
transfections were carried out with Fugene 6 (Roche), Fugene HD (Roche), or 
Effectene (Qiagen) reagents. MG132 proteasome inhibitor was purchased from 
Sigma. 
c-Myb stable knockdown 
Stable shRNA MCF-7 lines were created expressing either pRS-shMyb (5’-
CGTTGGTCTGTTATTGCCAAGCACTTAAA-3’) or pRS-shGFP (5’-
TGACCACCCTGACCTACGGCGTGCAGTGC-3’) (Cat. No. TR311329; Origene, 
Rockville, MD, USA).  Briefly, Phoenix 293T packaging cells were transfected with 
10 µg of retroviral cassette (pRS-shMyb or pRS-shGFP) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA), as per manufacturer’s instructions.  Media was 
changed 24 hours post-transfection and supernatant collected after 12 hours.  MCF-
7 cells were transduced by applying supernatents plus 75 µg polybrene.  Stable 
populations were obtained by culturing in 2 µg /mL puromycin for two weeks, and 
keeping under constant selection thereafter.  After two weeks, cells from the MCF-7 
pRS-shMyb line were plated at clonal density and >20 clones chosen to analyze for 
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efficient knockdown.  Clones with the greatest knockdown were kept for further 
analysis. 
Luciferase assay 
The Dual Light Combined Reporter gene assay detection system was 
purchased commercially (Applied Biosystems). Reporter constructs were transfected 
into H1299 cells, incubated for 24 hours, harvested according to the manafcturer’s 
protocol, and Luciferase and β-Galactosidase activity were detected. Assays were 
run in 96 well plate format on an Lmax microplate luminometer (Molecular Devices). 
Relative light units normalized by the luciferase activity/β-Gal ratio. 
Quantitative RT-PCR 
RNA was purified from WI38 cells using RNeasy mini kit (Qiagen). SYBR 
Green PCR master mix (Applied Biosystems) was combined with primers targeting 
exon 1-2 of Hep27. Primers: For 5’-AAGACCACGAATGCACCGAGAG, Rev 5’-
GGCAACTGCTGACAGCATA GTGG. Relative Hep27 mRNA levels were 
normalized with GAPDH internal control. 
Western blot analysis 
Cells were washed with PBS, lysed in Mammalian Protein Extraction Reagent 
(Thermo Scientific) supplemented  with 1X protease inhibitor cocktail, 1mM NaVO3, 
1mM PMSF, and 1 mM DTT. 5X Laemmli sample buffer was added to equivalent 
amounts of cellular lysates which were then resolved on 10% SDS-PAGE and 
transferred to Immobilon PVDF membranes. Membranes were blocked in 10% 
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nonfat dry milk in TBS-Tween-20 and probed with appropriate primary antibodies, 
followed by anti-mouse or -rabbit IgG-horseradish peroxidase (HRP)-conjugated 
secondary antibody (Amersham Biosciences). Membranes were then incubated in 
SuperSignal West Dura Extended Duration substrate or SuperSignal West Pico 
substrate (Thermo Scientific) and the signal developed on HyBlot CL 
autoradiography film (Denville Scientific Inc.). 
Densitometry 
UN-SCAN-IT gel (V 5.1) scanning software (Silk Scientific) was used to 
digitize all indicated blots. The ratio of p53:Actin was calculated per sample and the 
ratios then compared to the control ratio to determine fold differences. 
Colony Formation Assay   
Soft agar assays were performed in triplicate in six-well ultra-low attachment 
plates (Corning).  Briefly, a medium-agar mix was prepared by combining 2x RPMI-
1640 (Invitrogen, 23400-021), 5.6 mL 1x RPMI (Invitrogen), 2.4 mL FBS (Sigma), 
and 8 mL 1.8% Noble agar (Sigma, A5431-250G).  A volume of 2.3 mL of the 
medium-agar mix was added to each well, to create a bottom layer, and allowed to 
solidify.  MCF7 cells (shMYB or shGFP) were washed with PBS, trypsinized, 
counted, and 8,000 cells were combined with 3 mL of medium-agar mix to create the 
top agar layer in each well.  Once the top agar layer solidified, 0.5 mL of selective 
media (RPMI-1640, 10% FBS, 2 ug/mL puromycin) was added to each well and 
changed with fresh media every three days.  Cells were grown for 15-20 days until 
colonies were visible.  Colonies were visualized by removing liquid media, adding 
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200 microliters of  MTT dye (Cell-Titer 96, Promega #G4100), incubating for one 
hour at 37 C, followed by scanning the plates and manual counting of colonies.  
Statistical significance was calculated using a two-tailed t-test. 
Doubling Time Assay 
   MCF7 cells stably expressing shMYB or shGFP were seeded, in duplicate, 
into 10 centimeter dishes at 50,000 cells per plate.  Cells were allowed 48 hours of 
growth prior to the first counting (t=0), followed by counting at 48, 72, and 124 hours 
(Beckman Z1 Coulter Particle Counter).  Doubling times were estimated by linear 
regression. 
 
Results 
c-Myb is a transcriptional regulator of Hep27 
Previous gene microarray experiments indicated that one member of the Myb 
family, c-Myb, could induce Hep27 transcript levels (95, 102, 170).  Ectopic 
expression of wild type human c-Myb in WI38 cells induced an average 58-fold 
increase in Hep27 transcript levels (Fig. 4.1A), supporting the notion that c-Myb can 
promote Hep27 transcription. The c-Myb-induced increase in Hep27 transcript levels 
correlated with an increase in Hep27 protein levels in WI38 cells (Fig. 4.1B), 
indicating that c-Myb increases Hep27 in a dose dependent fashion. In contrast, 
stable knockdown of c-Myb in MCF7 cells resulted in undetectable levels of Hep27 
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protein when compared to a control GFP knockdown (Fig. 4.1C), signifying a tight 
correlation between c-Myb and Hep27 expression.  
The subset of c-Myb direct target genes is poorly defined and may largely 
vary by cell type and lineage, co-factor specificity, as well as temporal and spatial 
expression patterns (143).  A number of human genes including adenosine 
deaminase (ADA), c-Myc, and MAT2A have been reported to contain c-Myb sites 
within their promoter, as well as enhancer, regions (9). In order to determine if 
Hep27 is a direct c-Myb target gene, regions within the promoter and first intron 
were systematically queried for the c-Myb consensus site (C/T)AAC(G/T)G (60). The 
Hep27 gene contains two Myb Response Elements (MRE) at nucleotides -143 to -
138 and -39 to -34 upstream of the transcription start site (TSS) (Elements A and B, 
Fig. 4.2A), consistent with potential promoter function. In addition, two more MRE 
are located at nucleotides 2049-2054 and 2088-2093 downstream of the TSS 
(Elements C and D, Fig. 4.2A), consistent with potential enhancer function. The 
pGL3-Basic luciferase construct (Promega) contains a promoterless 1653 bp cDNA 
sequence coding for the luciferase gene. Element AB was placed 5’ of the Luc gene 
in pGL3-Basic to assess promoter activity, as is seen in vectors P1 and P1+EN. 
Element CD was placed 3’ of the SV40 Poly(A) signal in pGL3-Basic to assess 
enhancer activity, as seen in vectors EN and P1+EN.  Vector P2 containing the CD 
element in the 5’ orientation was used to assess if any c-Myb activity could occur in 
this region to drive luciferase expression.  
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This strategy for testing CD element enhancer function is consistent with the 
pGL3-Enhancer Luciferase construct (Promega), which places an SV40 enhancer 
element 3’ of the SV40 poly(A) signal. In addition, placing the CD element in the 3’ 
end of the gene more closely resembles the spacial orientation of elements AB in 
the promoter and CD in intron 1. Vector P1+EN does contain a promoter element 
and the addition of element CD does not enhance expression over Vector P1 alone. 
This demonstrates that even in the presence of the promoter element AB, element 
CD is not able to promote c-Myb activity. 
To assess the functional nature of these possible promoter and enhancer 
sequences, regions corresponding to nucleotides –400 to –1 (comprising sites A and 
B) and nucleotides 1964 to 2463 (comprising sites C and D) were amplified from 
U2OS genomic DNA and cloned into the pGL3-Basic luciferase reporter plasmid. 
Element AB was placed 5’ of the Luc gene in pGL3-Basic to assess promoter 
activity, as is seen in vectors P1 and P1+EN. Element CD was placed 3’ of the SV40 
Poly(A) signal in pGL3-Basic to assess enhancer activity, as seen in vectors EN and 
P1+EN, or 5’ of the Luc gene (Fig. 4.2B). The constructs were transiently expressed 
in H1299 cells in the presence or absence of c-Myb co-expression (Fig. 4.2C). c-
Myb promoted a significant increase in P1 (p= .0096), as well as P1+EN (p=.0423), 
relative light units (RLU) respectively, when compared to control pGL3-Basic activity. 
Conversely, the P2 and EN constructs, containing putative C and D elements, 
exhibited no significant increase in RLU. These data support a role for Hep27 as a 
direct c-Myb target gene. 
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c-Myb regulates p53 stability in a Hep27-dependent manner 
The well established paradigm for oncogenic signaling to p53 involves 
upregulation of the tumor suppressor p14ARF in response to aberrant activity of 
activated RAS, c-Myc, and E2F. Given the distinct function of p53 in monitoring 
oncogenic activity, we set out to determine if over-expressed c-Myb could also 
stabilize p53. Transient expression of c-Myb in p53 wild type MCF7 cells stabilized 
p53 in a dose-dependent fashion (Fig. 4.3A). The increase in p53 correlated with a 
parallel increase in Hep27 protein levels and p53-induced transactivation of p21. To 
determine if there was a connection between c-Myb induced Hep27 levels and 
increased stability of p53, Hep27 levels were knocked down in MCF7 cells and their 
response to c-Myb expression was assessed (Fig. 4.3B). c-Myb induced a dose-
dependent p53 stabilization and transactivation of p21 in the control scramble siRNA 
sample. In contrast, knockdown of Hep27 impaired c-Myb induced p53 stabilization 
and activation, thereby reducing p21 levels. Moreover, stable knockdown of c-Myb in 
MCF7 cells resulted in decreased Hep27 levels and p53 levels, indicating that 
physiological levels of c-Myb expression stabilizes p53 (Fig. 4.3C). c-Myb induced 
overall levels of Hep27, resulting in increased nuclear levels of mature Hep27 (Fig. 
4.3D).  
 
c-Myb expression in breast cancer cells retards cell proliferation 
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To gain more insight into the functional consequences of c-Myb modulation in 
breast cancer cells, we worked with our collaborator Aaron Thorner to assess 
proliferation rates of c-Myb stable knockdown cells. The average doubling time of 
MCF7 cells with stable knockdown of c-Myb was 3.2 hours faster than GFP 
knockdown controls (Fig. 4.4A). In addition, compared to control cells where colony 
counts were minimal, colony number and size were enhanced in c-Myb knockdown 
cells in a soft agar colony formation assay (Fig. 4.4B and C). These data 
demonstrate how the presence of highly expressed c-Myb in the luminal-type MCF7 
cells results in a decrease in proliferation rate, indicating that c-Myb has “tumor-
suppressor” type characteristics in this context. 
Together, this evidence suggests that c-Myb induced Hep27 expression is 
required for the p53 stabilizing and transactivating effects of c-Myb. The data provide 
evidence for a c-Myb-Hep27-Mdm2-p53 pathway. c-Myb induction of Hep27 
promotes mitochondrial matrix accumulation of the mature protein. A fraction of 
Hep27 is translocated to the nucleus leading to inhibition of Mdm2 and subsequent 
stabilization of p53 (Fig. 4.5).    
 
Discussion 
Our data demonstrate that mature Hep27 is partially translocated from the 
mitochondria to the nucleus. Nuclear localized Hep27 binds to Mdm2 and promotes 
p53 stabilization, thereby triggering transactivation of p53 downstream target genes 
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such as p21 (Fig. 4.5). The connection between aberrantly high expression of c-Myb 
and activation of p53, supports a model for an oncogene-tumor suppressor loop, 
where p53 monitors the activity of c-Myb via Hep27. Indeed, activated p53 has been 
reported to form a ternary complex with the co-repressor mSin3A and c-Myb, 
resulting in inhibition of c-Myb transcriptional activity (202). Moreover, p53 activation 
can also stimulate c-Myb proteasomal degradation in a Siah-dependent fashion. 
Given the role of c-Myb in promoting cell growth and proliferation, it is reasonable to 
expect that c-Myb may play a functional role in promoting or maintaining a malignant 
phenotype. At this time, it is unclear if the Hep27 locus or gene expression levels are 
altered in any way within c-Myb dependent tumor types.  
Here we present contrasting evidence that c-Myb overexpression in luminal 
type breast cancer cells has a negative impact on cell growth and proliferation. This 
is in part, due to our demonstration that oncogenic c-Myb can signal to p53 via 
Hep27. The signaling appears to be insufficient to drive p53-dependent apoptosis, 
but is sufficient to induce p53-dependent induction of p21, thereby retarding the cell 
cycle and slowing the rate of cell proliferation. The precise role and functional nature 
of Hep27 modulation of p53 remains to be determined. 
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Figure 4.1 The proto-oncogene c-Myb regulates Hep27 expression. (A) WI38 
fibroblasts transfected with control vector or c-Myb expression construct were 
incubated for 36 hours. mRNA was harvested and reverse transcribed for qRT-PCR 
analysis targeting exons 1-2. Results are presented as expression levels of Hep27 
relative to GAPDH control. (B) c-Myb expression construct was used to transfect 
WI38 cells for 36 hours. α-Hep27 antibody was used to detect Hep27 expression by 
western blot. (C) Short hairpin RNA constructs targeting GFP or c-Myb were used to 
establish stable MCF7 cell lines. α-c-Myb and α-Hep27 antibodies were used to 
detect endogenous c-Myb and Hep27 levels by western blot.   
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Figure 4.2 c-Myb directly promotes transcription of Hep27. (A) Schematic 
illustrating putative c-Myb response elements in the promoter and first intron of the 
Hep27 gene (Dhrs2). The consensus Myb Response Element (MRE) is shown. (B) 
Schematic showing pGL3 Basic Luciferase reporter constructs. P1, P2, EN, and 
P1+EN correspond to potential MRE as seen in C. P: Promoter, EN: Enhancer. (C) 
Luciferase reporter constructs were transfected into H1299 cells in the presence and 
absence of c-Myb co-expression for 36 hours. pGL3 Basic and c-Myb were 
transfected alone as controls, and β-Galactosidase expressed with all samples as a 
transfection control. Relative light units (RLU) represent relative expression of the 
luciferase/β-Gal ratio. Statistical analysis was performed using an unpaired t-test. 
Results are based on three independent experiments.   
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Figure 4.3 c-Myb induces p53 stabilization and activation in a Hep27 
dependent manner. (A) Expression construct expressing c-Myb was transfected 
into MCF7 cells for 24 hours and indicated proteins were detected by western blot. 
(B) RNAi scramble and Hep27 oligos were transfected into MCF7 cells and 
incubated for 48 hours. Cells were washed and an additional transfection performed 
with c-Myb expression construct. Cells were incubated an additional 24 hours and 
harvested for western analysis. (C) Short hairpin RNA constructs targeting GFP or c-
Myb were used to establish stable MCF7 cell lines. Endogenous c-Myb, Hep27, and 
p53 levels were detected  by western blot. (D) Expression construct for c-Myb was 
transfected into MCF7 cells for 24 hours. Whole cell lysate (Total) and Nuclear 
fraction (Nucleus) were assessed by western blot. Actin is a cytosolic control and 
Histone H3 is a nuclear control. 
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Figure 4.4 c-Myb knockdown promotes cell growth in breast cancer cells. (A) 
Short hairpin RNA constructs targeting GFP or c-Myb were used to establish stable 
MCF7 cell lines. Doubling time was calculated over 96 hours. (B) Soft agar colony 
formation assay using the cell lines described in A. Three replicate wells are shown 
for each sample. The number of foci were calculated and shown in (C).  
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Figure 4.5 A model for c-Myb-Hep27-Mdm2-p53 mitochondria to nucleus 
signaling. The proto-oncogene c-Myb induces expression of full length Hep27 pre-
protein. Hep27 is actively imported to the mitochondria by an N-terminal 
mitochondrial targeting signal (MTS). Once imported into the mitochondrial matrix, 
the MTS is cleaved off to produce mature Hep27 (Hep27m). A minor fraction of 
Hep27m translocates to the nucleus to bind to Mdm2, resulting in p53 stabilization 
and subsequent transactivation of downstream target genes. 
 
 
 
  
Chapter 5 
 
A role for Hep27 in human breast cancer 
co-authors: Aaron R. Thorner and Charles M. Perou 
 
Introduction 
 Breast cancer is the most common cancer diagnosed and the second leading 
cause of cancer death among women in the United States. Conventional parameters 
for determining prognosis include tumor size and histological grade, estrogen and 
progesterone receptor status, and lymph node status (25). Profiling based on 
intrinsic gene expression patterns facilitates classification of luminal epithelial, 
HER2+/ER-, basal-like, and normal breast-like subtypes (157). Each subtype is 
correlated to significant differences in patient outcome and may be a useful tool for 
prognosis and treatment assessment.  
  Here we provide a correlation between Hep27 and ER+ luminal breast 
cancer where Hep27 expression is positively correlated with overall survival, but 
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negatively correlated with chemotherapy therapeutic response. The data suggests 
the existence of an ER-c-Myb-Hep27-Mdm2-p53 functional pathway in the luminal 
epithelial subtype.  
 
Materials and Methods 
Antibodies and reagents 
The following antibodies were commercially purchased: mouse anti-Actin 
(Neomarkers), rabbit anti-c-Myb 45150. Hep27 antibody was generated as stated in 
chapter 2. Beta estradiol was purchased from Sigma. 
Cell culture 
MCF-7 cell lines were maintained in RPMI medium (without phenol red) 
supplemented with 10% fetal bovine serum, L-glutamine, 100 U/ml penicillin and 100 
ug/ml streptomycin at 5% CO2 in a humidified chamber.  
Microarray analysis 
Human breast tumor microarray data from a Swedish patient cohort (n=236) was 
used for all tumor analyses (120).  Tumors were classified into intrinsic breast cancer 
subtypes using the PAM50 classifier exactly as described in (154).  Disease-specific 
survival by subtype was visualized by a Kaplan-Meier survival plot and tested for 
significance using the chi-square test (WinSTAT v.2007.1).  Association of c-Myb or 
Hep27 expression with breast cancer subtypes, estrogen receptor status (n=232), or 
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p53 mutation status was tested for statistical significance by ANOVA using the R 
system for statistical computing (R Development Core Team, 2006, http://www.R-
project.org).  A 52-gene signature capable of predicting non-functional p53 (i.e. p53 
mutation signature) was applied to the Miller data as done previously (203).  The 
distribution of the p53 mutation signature across tumor subtypes was visualized by a 
box-and-whisker plot and statistical significance calculated by ANOVA. 
Kaplan-Meier survival analysis 
Samples were derived from the Netherlands Cancer Institute dataset of local-only 
treated breast cancer patients who received no adjuvant chemotherapy (n=165 for 
overall survival in comprehensive dataset, and n=72 for Luminal-A dataset). c-Myb and 
Hep27 were rank ordered and split in half into high and low values. Kaplan-Meier 
survival analysis was performed using Winstat 2.0 and p-values were generated using a 
standard chi-square analysis.  
Pathologic complete response (pCR) and residual disease (RD) were assessed 
using the Hess et al dataset (70). c-Myb and Hep27 were rank-ordered and split in half 
into high and low values. p-values were generated using a standard chi-square 
analysis. 
 
Results 
Hep27 correlates to the Luminal A breast cancer subtype 
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Our in vitro analyses have identified a mechanism for the involvement of Hep27 
in the p53 pathway through c-Myb signaling.  To determine if this pathway has any 
relevance for human breast cancer patients, we analyzed a well studied breast tumor 
microarray data set (120) (n=236) representing a large cohort of patient samples that 
contains survival data, p53 mutation status, and estrogen receptor (ER) status.  Tumors 
were classified into intrinsic subtypes (basal-like, HER2-enriched, luminal A, luminal B, 
and normal-like) using the PAM50 subtype predictor as described in (154), and disease-
specific survival was analyzed by the Kaplan-Meier estimator (Fig. 5.1A). Survival 
outcome across subtypes in this dataset was similar to that of other previously analyzed 
breast tumor microarray datasets (193), and therefore is appropriate for use in this 
study.  Stratifying samples by ER status, expression of Hep27 was determined to be 
significantly higher in the ER positive (ER+) tumors (Fig. 5.1B).  This is consistent with a 
role for direct ER regulation of c-Myb (38) and supports the notion that ER induced c-
Myb stimulates increased expression of Hep27 (Fig. 5.1C).  
Transcript levels of both c-Myb and Hep27 were shown to vary significantly 
across the breast tumor subtypes (Fig. 5.2A and B) in a manner consistent with ER 
status (i.e. highest in the ER+ subtypes of luminal A and B). Both c-Myb and Hep27 
expression levels were lowest in the typically ER negative (ER-) basal-like tumors. 
Hep27 expression levels were also high in the subset of HER2-enriched tumors, many 
of which were ER+ (37/50) and all of which show some luminal cell characteristics. 
p53 mutation frequency among the intrinsic subtypes tends to be high among the 
basal-like, Her2-enriched, and luminal B tumors, but low within luminal A tumors (192), 
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a pattern also observed within this data set (data not shown). Higher Hep27 expression 
was significantly associated with wild-type p53 tumors (Fig. 5.2C) in a manner 
consistent with elevated Hep27 expression in the luminal A subtype.  To assess p53 
functional status, we applied a gene signature capable of predicting non-functional p53 
(p53 mutation signature) (203) to the Miller dataset and found the mutation signature to 
be lowest in the luminal A tumors, indicative of a functional p53 pathway within this 
subtype (Fig. 5.2D).  We performed comparable tests on two other breast cancer 
datasets that did not have as complete a set of clinical and genomic data (i.e. UNC and 
NKI data sets, both lacking p53 mutation status) and observed similar results (data not 
shown). Together, these in vivo correlations suggest that due to c-Myb regulation of 
Hep27, the ER+ luminal A breast cancer subtype has high c-Myb and Hep27 levels. In 
addition, the ER+ luminal A tumors with high Hep27 levels tend to be associated with 
functional, wild-type p53 and overall better survival. This supports the possibility that an 
ER-c-Myb-Hep27-Mdm2-p53 pathway may modulate p53 function in luminal breast 
tumor subtypes, in particular, luminal A tumors. 
 
Hep27 as a diagnostic indicator 
The experimental biological evidence points toward a role for Hep27 in tumor 
suppression. Specifically, c-Myb induction of Hep27 will lead to Mdm2 inhibition and 
activation of p53, leading to delayed cell proliferation. We sought to determine if c-
Myb and Hep27 expression levels could predict overall survival (OS) in breast 
cancer. Microarray analysis of samples derived from breast cancer patients that had 
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received only surgical intervention, and no adjuvant chemotherapy, were split into 
high and low expression values and survival times plotted over 250 months. The 
high expression percentile of c-Myb (p=0.0024) and Hep27 (p=0.014) exhibited 
significant trends toward better overall survival in a mixed population of breast 
cancer patients (Fig. 5.3A and B). This was also true for Luminal A only subtypes, 
where high expression predicted increased survival for c-Myb (p=0.022) and Hep27 
(p=0.0403) (Fig. 5.3C and D). These data indicate that an intact c-Myb-Hep27-
Mdm2-p53 signaling pathway in breast cancer, particularly the Luminal A subtype, 
may be sufficient to retard progression of tumor growth and predict a better overall 
survival in patients undergoing local resection of tumors.  
Using split rank ordered expression analysis, we next examined the outcome 
of chemotherapeutic pathologic response. The high expression values for c-Myb and 
Hep27 had identical responses in terms of residual disease (RD) and pathologic 
complete response (pCR) (p=0.0327) (Fig. 5.3E). High expression resulted in 
enhanced resistance to chemotherapy as determined by the diminished pCR. When 
expression levels were low, patients had a greater overall response to treatment with 
less residual disease and longer complete response. These data indicate that breast 
cancer subtypes with an active c-Myb-Hep27-Mdm2-p53 pathway may exhibit 
greater resistance to chemotherapy, due to decreased cell cycling and proliferation; 
key parameters known to affect drug response. Further analysis is necessary to 
determine the contribution of a c-Myb-Hep27-Mdm2-p53 pathway to proliferation 
dynamics and drug response in Luminal A type breast cancers.  
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Discussion 
By analyzing human breast tumor microarray data, we observed Hep27 
expression as being highest in ER+ and p53 wild-type tumors, phenotypes 
characteristic of the luminal A subtype. Indeed, both c-Myb and Hep27 have increased 
expression in the luminal A subtype relative to the basal-like subtype, the latter being a 
subtype with tumors frequently ER- and p53 mutant.  Using a gene signature capable of 
predicting non-functional p53, the luminal A samples had the lowest expression of a p53 
mutation signature, indicative of normal p53 function.  These data suggest that the 
proposed c-Myb-Hep27-Mdm2-p53 pathway may exist in vivo and be functional in ER+ 
luminal A tumors, but not basal-like breast cancers. With an ER-c-Myb-Hep27-Mdm2-
p53 axis intact, these correlative findings could, in part, explain the relative 
chemotherapy insensitivity of luminal A cancers (154, 168). Due to potential Hep27 
mediated stabilization of p53, luminal A tumor response to chemotherapy may result in 
a p53 mediated cell cycle arrest and subsequent cytotoxic insensitivity. 
Crosstalk between the estrogen receptor and p53 has previously been 
suggested. T47D human breast cancer cells, containing a mutant form of p53, restored 
elevated p53 levels following treatment with estradiol (73). In addition, p53 wild type 
MCF7 breast cancer cell lines overexpressing Mdm2 demonstrated increased steady 
state levels of p53 in the presence of estradiol (173). Murine models assessing 
estrogen stimulation of the mammary gland reported not only increased levels of 
nuclear, functional p53 (90, 188), but also demonstrated that hormone stimulation is 
necessary for a maximal p53 mediated response to ionizing radiation (6). Finally, wild-
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type p53, but not mutant p53, was found to bind to the estrogen receptor in vivo and 
repress ER dependent transcriptional activity (222). An ER dependent c-Myb-Hep27-
Mdm2-p53 pathway could provide a molecular link between ER activation and p53 
stabilization in cells of the mammary gland. ER modulation of p53 could, in turn, result 
in p53 dependent down regulation of ER activity, supporting a negative feedback loop 
between the two.  
One defining feature of the luminal epithelial subtype is the presence of the 
estrogen receptor (ER). Unlike anti-hormone therapy today which remains the 
mainstay for treatment to attenuate the proliferation of ER positive breast cancers, 
historical treatment relied on the anti-tumor effects of estrogen agonists. During the 
1960’s, women were treated with high doses of the estrogenic compound 
diethylstilboestrol (84) where it was expected that 36% of patients would typically 
responded favorably (83). Moreover, it has been noted that the further a woman is 
into menopause, the greater potential success, in terms of tumor regression, she will 
have with estrogen therapy (62). This is also the case for women who have 
received, but developed resistance to, prolonged anti-estrogen therapy. 
Administration of estrogen agonists in these cases can lead to favorable treatment 
outcomes by triggering apoptosis of ER+ cells. Collectively, these observations 
suggest that antagonizing the long-term pro-growth and survival potential of 
estrogen stimulation actually sensitizes mammary cells to the apoptosis inducing 
effects of estrogen stimulation (176).  
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The apparent paradox between estrogen sustained growth or induction of 
apoptosis is not well understood, but several studies point toward both extrinsic and 
intrinsic mechanisms of estrogen induced apoptosis (112), pathways that are 
independent and dependent on p53 respectively. Here we provide a correlation 
between Hep27 and ER+ luminal breast cancer where Hep27 expression is 
positively correlated with overall survival. The data suggests the existence of an ER-
c-Myb-Hep27-Mdm2-p53 functional pathway in the luminal epithelial subtype. Given 
the potential connection of estrogen receptor signaling to p53 activity through c-Myb 
regulation of Hep27, the sensitization of estrogen induced apoptosis by ER 
inhibition, and the partial dependence of some ER positive cells on the apoptosis 
inducing effects of p53, investigation into the contribution of an ER-c-Myb-Hep27-
Mdm2-p53 pathway to estrogen induced apoptosis could provide a mechanistic link 
to explain the estrogen paradox in a subset of ER+ breast cancers. Future studies 
are necessary to assess the contribution of this pathway to overall survival, 
chemotherapy response, and apoptosis. 
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Figure 5.1 Hep27 correlates to estrogen receptor activity. The Miller et al., 2005 
dataset (n=236) was classified into the breast tumor intrinsic subtypes (Basal-like, 
HER2-enriched, Luminal A, Luminal B, and Normal-like) using the PAM50 predictor 
(154). (A) Kaplan-Meier survival analysis of disease-specific survival stratified by 
subtype. p-value was determined by log-rank test, testing the null hypothesis that the 
survival curves are identical across the subtypes. (B) Hep27 mRNA expression in 
ER- and ER+ tumors (n=232).  p-values calculated by t-test showing different 
expression values across ER status or biologically defined breast tumor subtypes. 
(C) MCF7 cells were incubated in the presence of 10nM β-Estradiol for 22 hours. 
Western blot illustrates accumulation of c-Myb and Hep27. 
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Figure 5.2 A potential c-Myb-Hep27-Mdm2-p53 pathway in breast cancer. (A) c-
Myb and (B) Hep27 expression varies by intrinsic subtype. p-values determined by 
ANOVA, testing the null hypothesis that all group means are equal. (C) Hep27 
expression in p53-mutant and p53-wild-type tumors. p-values calculated by t-test 
showing different expression values across ER status or biologically defined breast 
tumor subtypes. (D) A p53-mutation signature (203) was applied to this dataset and 
correlated with breast tumor subtype. p-values determined by ANOVA, testing the 
null hypothesis that all group means are equal. 
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Figure 5.3 Hep27 is positively correlated with overall survival and 
chemotherapy response. Split rank ordered expression of c-Myb (A and C) and 
Hep27 (B and D) were subject to Kaplan-Meier survival analysis. Overall survival 
n=165, Luminal-A survival n=72. (E) Response to chemotherapy was assessed by 
chi-square analysis using residual disease (RD) and pathologic complete response 
(pCR) as defining parameters. 
 
  
Chapter 6 
 
Summary and future directions 
 
Concluding remarks 
Here we report that Hep27 is a bona fide target gene of c-Myb in cell types 
with detectable Hep27 expression. As a mitochondrial matrix protein, we show that 
Hep27 can be actively imported to the mitochondria via an N-terminal mitochondrial 
targeting signal. Cleavage of the mitochondrial targeting signal produces a mature 
form of Hep27, which is then capable of translocating to the nucleus where it binds 
to the central domain of Mdm2, thereby promoting p53 accumulation and 
subsequent transactivation. Consistent with a role for p53 in monitoring sustained 
oncogenic activity, elevated c-Myb activity can enhance Hep27 expression levels, 
resulting in greater nuclear accumulation of Hep27 and therefore increased p53 
stabilization. In addition, probing large gene expression datasets of human breast 
tumor samples revealed a potential link between estrogen receptor (ER), c-Myb, 
Hep27, and wild-type p53 in the luminal A tumor subtype. Thus, we propose a novel 
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c-Myb-Hep27-Mdm2-p53 pathway that utilizes the extra-mitochondrial tumor 
suppressor function of Hep27 to modulate basal p53 function with potential 
implications for ER positive luminal breast cancers. 
Evidence has been presented for a novel Mdm2 regulatory pathway involving c-
Myb induction of the mitochondrial protein Hep27. Elevated expression of c-Myb 
promotes nuclear accumulation of Hep27 which is able to support p53 stability and 
transactivation of downstream target genes through inhibition of Mdm2. A c-Myb-
Hep27-Mdm2-p53 pathway may not only have implications in c-Myb dependent 
cancers, but may also play a potential role in physiological regulation of cell cycle 
dynamics during development and hematopoiesis, areas where c-Myb is known to play 
a critical role. Furthermore, this work sheds light on signaling pathways involved in 
cross-talk communication between the mitochondria and nucleus. Future investigation 
will aim at elucidating the roles of Hep27 in mitochondrial dynamics and metabolism, 
cell cycle regulation, and tumor suppressor function. 
 
Future direction 1: Determine the mitochondrial function of Hep27 
A recent report provides evidence ascribing carbonyl reductase function to 
Hep27 in vitro (179). SDR family members contain a highly conserved catalytic 
domain consisting of a YXXXK motif, where the tyrosine and lysine residues are 
absolutely essential for catalytic function. Hep27 contains an SDR catalytic motif 
from amino acids 185-189 defined as YNVSK. Specifically Tyr185 and Lys189 are 
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strictly conserved with other SDR family members, and therefore likely represent the 
carbonyl reductase catalytic domain of Hep27. Mitotracker CMXRos is a 
mitochondrion specific marker that contains a mildly thiol-reactive chloromethyl 
moiety. Upon entering a cell with actively respiring mitochondria, Mitotracker is 
oxidized, conjugated with proteins in the mitochondria, and is detectable by 
fluorescence microscopy. Since the fluorophore is dependent on oxidation for proper 
fluorescence, and ROS levels are typically higher for mitochondrion with greater 
membrane potential, Mitotracker can act as a semi-quantitative indicator of 
mitochondrial membrane potential by observing the intensity of fluorescence 
staining. Ectopic expression of wild-type Hep27, but not a mitochondrial-localized 
GFP protein (MTS-GFP) or a mitochondrial-excluded Hep27 (Hep27-DelN24), 
exhibited greater Mitotracker staining intensity (Fig. 6.1). This indicates that the 
enzymatic mitochondrial function of Hep27 may  promote mitochondrial membrane 
potential, and therefore increased mitochondrial function.   
The purpose of this section is to address whether or not the catalytic domain 
of Hep27 is required for increased mitochondrial membrane potential. Using site-
directed mutagenesis, Tyr185 will be changed to phenylalanine and Lys189 altered 
to isoleucine to generate a catalytic-deficient Hep27 enzyme. These point mutations 
have been specifically shown to completely eliminate enzymatic function in the 
catalytic YGVTK motif of pig 3α/β, 20β-hydroxysteroid dehydrogenase, another SDR 
family member (135). This construct will be transiently transfected to determine if the 
catalytic domain mutation inactivates the observed enhancement of Mitotracker 
staining. If Hep27 is determined to have enzymatic function in the mitochondrial 
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matrix, follow up analysis will assess the enzymatic function in peroxisomes, attempt 
to identify endogenous substrates, and ultimately determine the putative metabolic 
contribution of Hep27 to the cell.   
 
Future direction 2: Characterize the mechanism of Hep27 nuclear  
translocation 
The mechanism underlying the translocation of Hep27 from the mitochondrial 
matrix to the nucleus is unclear. A recent study describes vesicular carriers, termed 
mitochondria derived vesicles (MDV), that can selectively transport cargo derived 
from all mitochondrial compartments to peroxisomes (139). Interestingly, Hep27 has 
also been reported to localize to peroxisomes via a C-terminal peroxisomal targeting 
signal (66). Given the importance of vesicular trafficking within the cell to relay 
biochemical messages from various subcellular compartments, it is tempting to 
speculate that mitochondria-derived vesicles can selectively transport mature Hep27 
from the mitochondria to other observed locations like peroxisomes and the nucleus. 
Further investigation is warranted to determine the exact nature of Hep27 
translocation from the mitochondria to the nucleus. 
 
Future direction 3: Assess the metabolic modulation of p53 by Hep27 
In order to carry out normal metabolic functions to maintain cell growth and 
proliferative homeostasis, eukaryotic cells must meet energetic demands through 
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ATP production. The primary carbon source for ATP production is glucose, but lipids 
and amino acids can also be catabolized to provide fuel for energy production. ATP 
synthesis can occur through the more “ancient” process of glycolysis where, through 
a series of ten intermediate steps, glucose is converted into pyruvate, generating 
two ATP and two NADH molecules in the process. The rate of glucose breakdown in 
glycolysis is generally considered to be a fairly rapid process, however the ATP yield 
from high energy glucose is low and inefficient. The available pool of pyruvate can 
oxidize NADH back to NAD+ through the anaerobic process of lactic acid 
fermentation, producing lactic acid as a byproduct. In eukaryotic cells, the second 
form of ATP production is aerobic respiration which occurs in the mitochondria. 
Pyruvate is decarboxylated to Acetyl-CoA generating 2 ATP through substrate level 
phosphorylation. Acetyl-CoA is fully oxidized during the Krebs cycle to produce 
NADH, the substrate necessary for generating the electrochemical gradient across 
the electron transport chain. The proton gradient is then used to drive efficient and 
high yield ATP production through oxidative phosphorylation, generating a total of 36 
ATP for every glucose molecule. Glycolysis and mitochondrial respiration are both 
used simultaneously to yield the net energy necessary for eukaryotic cell function, 
but the balance between the two processes is tightly regulated and adaptable to 
varying metabolic conditions. While the yield of ATP from glycolysis may be low, it is 
a rapid process that may become the preferred method of ATP production in 
contexts where high energy demands are necessary such as contraction of muscle 
fibers, or increased biosynthesis of proteins and cell structures. Glycolysis may also 
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be more relied on during conditions of mitochondrial dysfunction where oxygen 
concentrations are low or the mitochondria is otherwise impaired.   
Research over the past decade has begun to emphasize the role of p53 in 
regulating cell metabolism under “non-stressed” conditions. Since a cell may be 
constantly undergoing metabolic perturbations due to constantly changing 
physiological conditions, a more accurate representation of p53 in this context is a 
metabolic stress response regulator; altering cellular conditions during non-lethal or 
“low-stress” conditions. Metabolic stress can come in a variety of forms including 
increased or decreased ATP demands, carbon source availability, fluctuating oxygen 
concentrations, growth factor signaling, and any other number of common “day-to-
day” stress a cell might encounter. Stabilization of p53 has been demonstrated to 
decrease glycolysis and enhance aerobic respiration; while loss of the gene 
corresponds to decreased mitochondrial biogenesis, lowered oxygen consumption, 
and increased rates of glycolysis. Interestingly, in the presence of wild-type p53, net 
ATP production remains stable, but is skewed in favor of mitochondrial respiration. 
However, when p53 function is lost, ATP is primarily derived through glycolytic 
energy production (111). In part, this observation has led to some insight regarding 
the genetic switches accounting for the Warburg effect. This is the observation that, 
even under conditions of high oxygen availability,  most cancer cells shift ATP 
production from oxidative phosphorylation in the mitochondria, to the less efficient (in 
terms of total energy produced from glucose) process of glycolysis. Given that p53 is 
mutated or inactivated in the majority of human cancer, it is reasonable to suspect 
that p53 plays a role in governing the switch from aerobic to anaerobic metabolism.  
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As a transcription factor, p53 regulates gene expression patterns to alter 
genetic programs, a paradigm holding true for metabolic regulation as well. A 
number of p53 target genes have been identified that provide a partial explanation 
for the observation of p53 as a metabolic switch. One of the first metabolic genes to 
be identified as a p53-regulated target is Phosphoglycerate Mutase (PGM) (86), a 
glycolytic enzyme that catalyzes the reversible conversion of 3-phosphoglycerate to 
2-phosphoglycerate through a 2,3 bisphosphoglycerate intermediate. PGM is 
actually repressed by p53 and in doing so, glycolytic function is decreased. 
However, since PGM is not critical for regulation of glycolysis, it only created an 
initial framework for explaining the role of p53 in shifting metabolic tides. A second 
gene identified as a p53-inducible target gene was Synthesis of Cytochrome c 
Oxidase 2 (SCO2) (111). SCO2 regulates the cytochrome c oxidase (COX) complex 
of the electron transport chain where the majority of oxygen is consumed during 
oxidative phosphorylation. Targeted disruption of one Sco2 allele in mice was 
sufficient to recapitulate the altered distribution of ATP production observed in p53 
null mice, where glycolysis is favored over respiration. Expression of SCO2 in p53 
null HCT116 cell lines restored the oxygen consumption levels seen in p53 wild type 
mice, indicating that SCO2 was critical in driving ATP production in the mitochondria. 
Another p53-inducible target gene is TP53-induced Glycolysis and Apoptosis 
Regulator (TIGAR), a gene that inhibits glycolysis by lowering Fructose-2.6-
bisphosphate levels (8). This favors the accumulation of Fructose-1,6,bisphosphate  
which is effectively shunted into the Pentose Phosphate Pathway to produce 
NADPH nucleotides. An additional biological effect of TIGAR expression is to lower 
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detrimental levels of reactive oxygen species (ROS) in the cell and enhance 
resistance to apoptotic stimuli. By doing so, TIGAR has been proposed to act as a 
switch determining p53 dependent downstream responses. The latest gene to be 
identified as a p53-regulated metabolic target is Guanidinoacetate Methyltransferase 
(GAMT), an enzyme critical for creatine biosynthesis (74). GAMT catalyzes the 
conversion of guanidinoacetate to creatine from glycine, arginine, or methionine 
substrates. Creatine is produced from these amino acids primarily in the kidneys and 
liver where it is secreted into peripheral blood circulation for utilization by muscle 
cells for energy production. Specifically, once in muscle cells, creatine enhances 
ATP recycling by using a phospho-creatine intermediate to convert ADP back to the 
usable ATP. On an additional note, under glucose deprived conditions, GAMT 
enhances Fatty Acid Oxidation (FAO), thereby enhancing this alternative fuel source 
for maintenance of energy production. Taken together, these genes provide partial 
mechanistic insight to the function of p53 in surveying metabolic conditions and 
driving a shift toward aerobic respiration. Moreover, this evidence highlights how 
modulation of p53 levels may be imperative to regulating the cellular response to 
day to day common metabolic stressors. In doing so, p53 would need to 
transactivate a host of target genes to adapt to changing metabolic conditions, but 
do so largely at the expense of activating the more well characterized hallmark 
functions of cell cycle arrest, apoptosis, or senescence, functions that need not be 
mutually exclusive from metabolic regulation, but may be appropriately attenuated in 
the face of mild physiological stress. 
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Additional metabolic targets of p53 include a number of antioxidant genes that 
serve to maintain homeostasis of reactive oxygen species (ROS). Several 
antioxidants have been reported to be downstream transcriptional targets of p53 and 
include catalase (CAT), manganese superoxide dismutase 2 (SOD2), glutathione 
peroxidase (GPX1), and sestrins 1 and 2 (SESN1/2) (145). Basal p53 function has 
been reported to be essential for ROS regulation under conditions of low stress 
(172). Since the mitochondria, specifically the electron transport chain, are the 
primary intracellular source or ROS, it stands to reason that p53-mediated increase 
in oxidative phosphorylation may be coupled with p53 induced antioxidant genes to 
offset ROS generated from enhanced mitochondrial function.  
Louis Pasteur made the observation, derived from studies in yeast in 1857, 
that oxygen rich conditions inhibited fermentation. The Pasteur effect, as it came to 
be known, described the mechanism whereby oxygen flux dictated the utilization of 
anaerobic glycolysis for ATP production in yeast. Bypassing the Pasteur effect was 
the integral component of the Warburg effect, whereby cancer cells rely on 
constitutively high levels of glycolysis to metabolize enhanced uptake of glucose 
(215). Warburg proposed that normal aerobic respiration must be permanently 
“damaged” in some fashion, resulting in attenuated capacity to reduce oxygen. The 
misnomer “aerobic glycolysis” was coined to describe the Warburg phenomenon and 
to account for his observation. A colleague of Warburg, Feodor Lynen, put forth an 
alternative hypothesis to account for the respiratory defects seen in cancer cells. 
The premise of Lynen’s hypothesis stated that aerobic respiration was not 
permanently damaged, but rather enhanced rates of glycolysis stem from the 
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inability to generate ATP from the mitochondria due to uncoupling of mitochondrial 
membrane potential from ATP synthesis (174). Essentially, uncoupling the electron 
transport chain from ATP synthesis would lead to cellular compensation for energy 
production through increased rates of glycolysis.  
Interestingly, mitochondrial uncoupling has been consistently demonstrated to 
promote lipid metabolism, specifically Fatty Acid Oxidation (FAO). Treatment of 
mitochondria with chemical uncouplers such as 2,4-Dinitrophenol was shown by 
Lynen and colleagues to promote FAO. In contrast, the cell utilizes a natural 
mechanism via uncoupling proteins to promote depletion of mitochondrial membrane 
potential, a process that coincides with enhanced FAO. For instance, inhibition of 
biological uncoupling proteins like UCP2, blunts the rate of lipid oxidation in the 
mitochondria (181), indicating that mitochondrial uncoupling may be a natural 
process associated with FAO. Generally speaking, FAO starts with import of fatty 
acids derived from ingested or stored triglycerides across the plasma membrane into 
the cytosol. The carbon length of fatty acids is highly variable, ranging from typically 
less than six carbons for short chain fatty acids, and greater than 22 carbons for very 
long chain fatty acids. All fatty acids destined for the mitochondria must be actively 
transported by the carnitine system, whereby carnitine palmitoyl transferase I and II 
shuttle fatty acids under approximately 20 carbons into the matrix compartment for 
oxidation. Beta-oxidation of fatty acids breaks down fatty acids two carbons at a time 
to generate acetyl-CoA which can substitute for pyruvate derived acetyl-CoA derived 
from glucose to generate energy through oxidative phosphorylation. Long chain fatty 
acids, those greater than 20 carbons, must first be broken down in peroxisomes to a 
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manageable size for mitochondrial import. Peroxisomal beta oxidation of fatty acids 
does not generate ATP, but rather, the electrons are transferred to oxygen to 
generate hydrogen peroxide. Under conditions of glucose deprivation, or high fat 
consumption, fatty acid oxidation provides an abundant store of available energy by 
supplying acetyl-CoA to the Krebs cycle to maintain mitochondrial respiration and 
adequate energy production.  
When put into a collective perspective, the aforementioned observations 
support the notion that energy homeostasis is regulated through a balance between 
two arms of metabolism: glucose and lipid metabolism (Fig. 6.2). In fact, the two 
arms of metabolism may be dependent on one another for optimal function. So 
under the current model I have proposed, if the two energy systems are concurrently 
active, the key to energy homeostasis is to regulate the balance between the two 
arms of metabolism. Under glucose-rich conditions, p53 levels would be low, fatty 
acid oxidation is largely suppressed, and glycolysis derived pyruvate can supply 
sufficient acetyl-CoA to the mitochondria for aerobic respiration. Under glucose 
deprived conditions, where p53 levels are known to rise (50), glucose metabolism is 
largely suppressed, and the balance is shifted toward fatty acid oxidation to support 
mitochondrial respiration. In this context, p53 acts as a metabolic switch to monitor 
energy homeostasis and shift the utilization of carbon sources during metabolic 
perturbations. 
Where does Hep27 fit into the picture? Beginning with localization, Hep27 is 
found primarily in the mitochondrial matrix. In addition, a C-terminal peroxisomal 
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targeting signal was found to actively import Hep27 into peroxisomes. Finally, 
according to data in this work, Hep27 is also constitutively localized to the nucleus at 
a level dependent on, and parallel to, mitochondrial Hep27 levels. Given that Hep27 
1) promotes an increase in mitochondrial membrane potential, 2) is localized to the 
mitochondrial matrix and peroxisomes, 3) is most abundantly expressed in the liver, 
a tissue where lipid metabolism is highly active, these data suggest that Hep27 may 
be involved in lipid metabolism. Based on this reasoning, an a priori hypothesis 
would predict Hep27 has a role in beta oxidation of very long chain fatty acids. So 
why is Hep27 also found in the nucleus? If modulation of p53 activity is an important 
component to mediate the shift away from glucose metabolism, in favor of fatty acid 
oxidation, then Hep27 acts as a “rheostat” or modulator of p53 function. Increasing 
Hep27 levels indicates an increased capacity for fatty acid oxidation, as a result p53 
levels are increased to alter genetic programming that can attenuate the glucose 
metabolic arm, promote the fatty acid oxidation arm, increase oxygen reduction 
capacity of the mitochondria, and enhance expression of antioxidant genes that can 
antagonize increased ROS generated from both peroxisomal and mitochondrial fatty 
acid beta oxidation, thereby supporting lipid metabolism and overall energy 
homeostasis (Fig. 6.2). In my view, this hypothetical model represents the future 
framework for Hep27 research. 
Can such a model for p53-mediated regulation of energy homeostasis under 
normal metabolic conditions be reconciled with the observations of Otto Warburg 
and Feodor Lynen? Cancer cells are known to require upregulated metabolism to 
support enhanced rates of cell growth and proliferation.  Numerous studies 
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measuring uptake of radiolabeled glucose of tumors in vivo support the notion that 
cancer cells rely heavily on glycolysis for ATP production. However, what about 
reliance on lipid metabolism? Would cancer cells not resort to any mechanistic 
means necessary to adapt cellular programming to maximize energy production? 
Recent evidence in leukemia cells supports the observation that some cancer cells 
may also be equally dependent on fatty acid oxidation to support energetic 
requirements (175). In addition, p53 function is lost in the majority of cancers, 
explaining, in part, loss of a functional surveillance system to suppress glucose 
metabolism. Based on our limited anecdotal evidence, Hep27 is expressed only in 
cancer types that retain functional wild-type p53. In these cell types, if Hep27 has a 
bona fide role in fatty acid oxidation, is wild-type p53 preserved to partially suppress 
glucose metabolism, and instead enhance the reliance on fatty acids as a carbon 
source for mitochondrial function? Within the current hypothetical model (Fig. 6.2), 
cancer cells with functional p53 and Hep27 expression may be partially dependent 
on fatty acid oxidation for energy generation. In cancer cells with p53 deficiency, 
mitochondrial respiration is impaired (consistent with Warburg), but fatty acid 
oxidation may be impaired as well (consistent with Lynen); therefore, these cells 
may be highly dependent on glycolysis for production of energy. Additional 
investigation is necessary to determine the contribution of Hep27 to p53 modulation 
of metabolism under normal conditions, and likewise, how this system may be 
adapted under malignant conditions.  
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Figure 6.1 Hep27 may promote mitochondrial respiration. Plasmids expressing 
the indicated proteins were transiently transfected in U2OS cells for 24 hours. 
Mitotracker CMXRos was added 30 min prior to formalin fixation and visualization by 
fluorescence microscopy.  
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Figure 6.2 Proposed integrated model for metabolic function of Hep27 and 
p53. Hep27 may have a role in peroxisomal and mitochondrial beta-oxidation of very 
long chain fatty acids. The nuclear function of Hep27 may be to modulate p53 
function to attenuate glucose oxidation, promote fatty acid oxidation, and increase 
antioxidants to antagonize ROS generated from enhanced peroxisomal and 
mitochondrial activity. 
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